HIV positive; documentation of HIV-1 infection by means of any one of the following:\r\n* Documentation of HIV diagnosis in the medical record by a licensed health care provider;\r\n* Documentation of receipt of antiretroviral therapy (ART) by a licensed health care provider;\r\n* HIV-1 RNA detection by a licensed HIV-1 RNA assay demonstrating > 1000 RNA copies/mL;\r\n* Any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV-1 western blot confirmation or HIV rapid multispot antibody differentiation assay\r\n* NOTE: A “licensed” assay refers to a United States (US) Food and Drug Administration (FDA)-approved assay, which is required for all investigational new drug (IND) studies
Individuals who are known to be human immunodeficiency virus (HIV) infected are eligible (note: HIV testing is not required for entry into the study)
Patients with a known history of human immunodeficiency virus (HIV) must have CD4 count >= institutional lower limit of normal within 28 days prior to registration
Human immunodeficiency virus (HIV) infected patients are eligible provided they meet all other eligibility criteria, and:\r\n* There is no prior history of acquired immunodeficiency syndrome (AIDS) defining conditions other than historically low CD4+ T-cell count or B-cell lymphoma\r\n* In the opinion of an expert in HIV disease, prospects for long-term survival are excellent were it not for the diagnosis of lymphoma\r\n* Use of HIV protease inhibitors as part of the anti-HIV regimen OR as a pharmacologic booster is not allowed\r\n* Zidovudine is not allowed\r\n* Once daily combination pills for HIV containing a pharmacologic booster such as cobicistat are not allowed\r\n* Patients with multi-drug resistant HIV are not eligible
Patients who have a history of and are known to be serologically positive for human immunodeficiency virus (HIV) and are receiving antiviral therapy; baseline testing is not required
Negative screening test results for human immunodeficiency virus (HIV), hepatitis B and C; if positive results are not indicative of true active or chronic infection, the subjects can enter the study after discussion with the principal investigator
Known human immunodeficiency virus (HIV) infection, solid organ transplantation, or other immunosuppressed state (for treatment phase)
Immunosuppressed status due to known human immunodeficiency virus (HIV) infection, severe uncontrolled diabetes, concurrent hematological malignancy, or other comorbidities
Has a diagnosis of immunodeficiency including subjects infected with human immunodeficiency virus (HIV)
SAFETY RUN-IN: Patients known to be carriers of human immunodeficiency virus (HIV1/2)
RANDOMIZED PHASE II CLINICAL TRIAL: Patients known to be carriers of human immunodeficiency virus (HIV1/2)
Recipients of organs from human immunodeficiency virus (HIV) or HBsAg positive donors.
Known history of human immunodeficiency virus (HIV); testing is not required in the absence of history
Human immunodeficiency virus (HIV) positive at time of procurement cells for CTL generation
Participants with a known history of human immunodeficiency virus (HIV) are ineligible because of the potential for pharmacokinetic interactions with MCS110, dabrafenib, and trametinib with antiretroviral agents. In addition, these participants are at increased risk of lethal infections when treated with marrow-suppressive therapy
Active infection or ongoing antiviral medication for viral infections including hepatitis B, hepatitis C, or human immunodeficiency virus (HIV); screening for chronic conditions is not required; HIV-positive participants on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with selumetinib or osimertinib
Subjects with a known history of human immunodeficiency virus (HIV), including patients with controlled disease on antiretroviral therapy; HIV testing is not required as part of screening for this study
Obtained within 14 days prior to C1D1: Rapid human immunodeficiency virus (HIV) 1/2 antibodies negative
Current evidence of any of the following:\r\n* Uncontrolled hypertension despite addition or adjustment of antihypertensive regimen\r\n* Gastrointestinal disorder affecting absorption\r\n* Active infection (e.g., human immunodeficiency virus [HIV] or viral hepatitis) or other medical condition that would make prednisone/prednisolone (corticosteroid) use contraindicated
Patients infected with hepatitis B, C or human immunodeficiency virus (HIV), unless they are on stable and effective antiviral treatment
Patients with human immunodeficiency virus (HIV) who are unable or unwilling to stop antiretroviral therapy for the duration of therapy may not be enrolled
The patient is known to be positive for the human immunodeficiency virus (HIV). The effect of BPM31510 on HIV medications is unknown. Note: HIV testing is not required for eligibility, but if performed previously and was positive, the patient is ineligible for the study.
Human immunodeficiency virus (HIV) positive or other acquired immunodeficiency that, as determined by the PI, interferes with the assessment of PID severity and/or the attribution of clinical manifestations of immunodeficiency to a PID
Know HIV virus infection
Hepatitis B and C negative (unless the result is consistent with prior vaccination or prior infection with full recovery); human immunodeficiency virus (HIV) negative
If patient is known to be human immunodeficiency virus (HIV) positive, they will not be eligible for the protocol; HIV testing is not mandatory prior to protocol enrollment
Patients with known human immunodeficiency virus (HIV) infection or hepatitis B or C infection; HIV testing is not mandated and is to be performed at the discretion of the treating investigator
Known positive for human immunodeficiency virus (HIV) or infectious hepatitis, type B or C; HIV patients are at increased risk of lethal infections when treated with marrow-suppressive therapy
Multidrug resistant HIV not amenable to long-term suppression based on either or both:\r\n* Clinical history of poor adherence to multiple antiretroviral drugs deemed sufficient to render effective HIV control unattainable\r\n* HIV mutational analysis (genotyping and/or phenotyping) that reveals high-level resistance such that a combination regimen comprised of agents from at least two drug classes cannot be devised to suppress HIV long-term\r\n* Refusal to adhere to HAART
Patients who are known to be serologically positive for human immunodeficiency virus (HIV). This includes HIV patients on antiretroviral therapy due to the potential for pharmacokinetic interactions with olaparib
Patients with known positivity for human immunodeficiency virus (HIV); baseline testing for HIV is not required. High-dose ascorbate acid is a known CYP450 3A4 inducer, which results in lower serum levels of antiretroviral drugs
Patients known to be human immunodeficiency (HIV)-positive must not have multi-drug resistant HIV infection, CD4 counts < 150/ul or other concurrent acquired immunodeficiency syndrome (AIDS)-defining conditions; serologic screening for HIV is required within the 6 months prior to study enrollment
Severely compromised immunological state, including being positive for the human immunodeficiency virus (HIV)
Participant has known HIV infection (due to potential drug-drug interactions between antiretroviral medications and venetoclax) HIV testing will be performed at Screening, only if required per local guidelines or institutional standards.
HIV-positive; documentation of HIV-1 infection by means of any one of the following: \r\n* Documentation of HIV diagnosis in the medical record by a licensed health care provider\r\n* Documentation of receipt of antiretroviral therapy (ART) (at least two different medications) by a licensed health care provider (documentation may be a record of an ART prescription in the participant’s medical record, a written prescription in the name of the participant for ART, or pill bottles for ART with a label showing the participant’s name)\r\n* HIV-1 ribonucleic acid (RNA) detection by a licensed HIV-1 RNA assay demonstrating > 1000 RNA copies/mL\r\n* Any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV-1 Western blot confirmation or HIV rapid multispot antibody differentiation assay\r\nNOTE: A “licensed” assay refers to a United States (U.S.) Federal Drug Administration (FDA)-approved assay, which is required for all investigational new drug (IND) studies
Has active human immunodeficiency virus (HIV) infection (as manifested by presence of HIV 1/2 antibodies and/or positive HIV enzyme-linked immunosorbent assay [ELISA]/western blot assays)
Human immunodeficiency virus (HIV) infection as detected through any laboratory method (e.g., enzyme-linked immunosorbent assay, Western Blot, RNA PCR). [Note: Testing to confirm the absence of HIV infection is required at screening unless testing was performed by the local laboratory within 6 months prior to screening.]
Participants that are cancer survivors or those with human immunodeficiency virus (HIV) will not be excluded from the study
Documented negative serologic testing for human immunodeficiency virus (HIV)
Patients with positive human immunodeficiency virus (HIV) status and currently requiring treatment with agents known to sensitize to irradiation, such as protease inhibitors, will be excluded
Participants with known human immunodeficiency virus (HIV); due to lack of available safety data for eribulin therapy in HIV infected patients.
Human immunodeficiency virus (HIV)-positive patients are excluded because these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy
Patients infected with hepatitis B, C or human immunodeficiency virus (HIV), unless they are on stable and effective antiviral treatment
Patients with human immunodeficiency virus (HIV1/2); an HIV test must be performed to confirm status prior to enrollment
Known human immunodeficiency virus (HIV)-positive unless on highly active antiretroviral therapy (HAART), and/or known Hepatitis B or C on treatment. Drug interactions between those agents and these experimental agents are wholly unknown (screening not required).
Human immunodeficiency virus (HIV)-positive patients may be considered for this study only after consultation with a National Institute of Allergy and Infectious Diseases (NIAID) physician
Participant has known Human Immunodeficiency Virus (HIV) infection (due to potential drug-drug interactions between antiretroviral medications and venetoclax). HIV testing will be performed at Screening, if required per local guidelines or institutional standards.
History of immunosuppression or autoimmunity, including human immunodeficiency virus (HIV), and organ or stem cell transplant, or an autoimmune condition previously treated with immunosuppressive therapy
Subjects with active uncontrolled infection or who are human immunodeficiency virus (HIV) positive (subjects with acute infections requiring treatment should delay screening/enrollment until the course of therapy has been completed and the event is considered controlled)
Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) even if fully immunocompetent on antiretroviral therapy (ART)—due to the unknown effects of HIV on the immune response to combined nivolumab plus ipilimumab or the unique toxicity spectrum of these drugs in patients with HIV
HIV positive; documentation of HIV-1 infection by means of any one of the following:\r\n* Documentation of HIV diagnosis in the medical record by a licensed health care provider;\r\n* Documentation of receipt of ART (at least three different medications) by a licensed health care provider (documentation may be a record of an antiretroviral therapy (ART) prescription in the participant’s medical record, a written prescription in the name of the participant for ART, or pill bottles for ART with a label showing the participant’s name);\r\n* HIV-1 ribonucleic acid (RNA) detection by a licensed HIV-1 RNA assay demonstrating > 1000 RNA copies/mL;\r\n* Any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV-1 western blot confirmation or HIV rapid multispot antibody differentiation assay\r\n* NOTE: a “licensed” assay refers to a United States (U.S.) Food and Drug Administration (FDA)-approved assay, which is required for all investigational food drug (IND) studies
Known history of immunodeficiency (human immunodeficiency virus [HIV] 1/2 antibodies); this medical entity can be exacerbated by PD-1 blockade
Active hepatitis, known human immunodeficiency virus (HIV), or other condition that requires immunosuppressive therapy, including current use of high dose systemic corticosteroids
Human immunodeficiency virus (HIV) infection confirmed by nucleic acid testing (NAT)
Human immunodeficiency virus (HIV)-positive patients, patients with acquired or congenital immunodeficiency conditions, those on chronic systemic immunosuppressants (requiring > 10 mg of prednisone or equivalent/day), those with active autoimmune disease are excluded from the study
Not be in an immunosuppressed state (e.g. human immunodeficiency virus [HIV], use of chronic steroids)
Active autoimmune disorders, including patients known to be human immunodeficiency virus (HIV) positive, or those requiring chronic steroid administration (excluding inhaled steroids)
Human immunodeficiency virus (HIV) positive; HIV results will be determined by nucleic acid testing
Willing to have documentation of HIV status
A recognized immunodeficiency disease including human immunodeficiency virus (HIV) infection (and other cellular immunodeficiencies, hypogammaglobulinemia or dysgammaglobulinemia; subjects who have hereditary, congenital or acquired immunodeficiencies).
Patients with other diseases that in the opinion of the treating physician pose a higher risk for treatment with ibrutinib therapy including active human immunodeficiency virus (HIV) infection and bleeding disorders
For dose-escalation cohort only, known positivity for human immunodeficiency virus (HIV); baseline testing for HIV is not required; HIV positive patients will be eligible for the dose-expansion cohort
History or evidence of sarcoma associated with immunodeficiency states (e.g.: hereditary immune deficiency, human immunodeficiency virus (HIV), organ transplant or leukemia)
Human Immunodeficiency Virus (HIV)-infection is not an exclusion criterion if it is controlled with anti-retroviral drugs that are unaffected by concomitant enzalutamide.
Known history of human immunodeficiency virus (HIV) or autoimmune diseases requiring immunosuppressant drugs
Not be in an immunosuppressed state (e.g. human immunodeficiency virus positive [HIV +], use of chronic steroids [> 1 month])
Known human immunodeficiency virus (HIV)-positive individuals; high-dose ascorbate acid is a known CYP450 3A4 inducer, which results in lower serum levels of antiretroviral drugs; a clinical trial designed to address these interaction issues is more appropriate than this phase 2 study
Immunosuppression (human immunodeficiency virus [HIV] positive, heme/oxygenase [h/o] transplantation, lupus on immunosuppressive medication, etc.)
Research participants who have confirmed human immunodeficiency virus (HIV) within 4 weeks of screening
Previous therapy with a human immunodeficiency virus (HIV) protease inhibitor
Research participants who have tested human immunodeficiency virus (HIV) positive, or have active hepatitis B or C infection based on testing performed within 4 weeks of enrollment
Comorbid conditions that, in the opinion of the investigator, would complicate safety or compliance such as known human immunodeficiency virus (HIV) or current substance abuse
The patient has a history of human immunodeficiency virus (HIV) or other known cause of immunosuppression, or is actively taking immunosuppressive medications due to organ transplantation, rheumatoid disease, or other medical conditions
Human immunodeficiency virus (HIV)-infected patients should be receiving or willing to initiate an effective combination antiretroviral therapy (cART) regimen
Patients must be human immunodeficiency virus (HIV) negative, and have negative serologies for hepatitis C
Patients must have an expected survival without treatment of > 60 days and must be free of major infection including human immunodeficiency virus (HIV)
Severely immune-compromised (other than being on steroids) including known human immunodeficiency virus (HIV) infection
Known history of human immunodeficiency virus (HIV) infection. Testing for HIV status is not necessary unless clinically indicated
Persistently uncontrolled diabetes mellitus, oxygen-dependent lung disease, chronic liver disease, or human immunodeficiency virus (HIV) infection
Known history of human immunodeficiency virus (HIV) seropositivity as these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy and the potential pharmacokinetic interaction between antiretroviral therapy and the investigational agent
No uncontrolled bacterial, viral, or fungal infection (infection is permitted if there is evidence of response to medication)\r\n* Note: human immunodeficiency virus (HIV)-infected patients are potentially eligible; eligibility of HIV-infected patients will be determined on a case-by-case basis
Patients known to be human immunodeficiency virus (HIV)-positive (the concern for opportunistic infection and hematologic reserve are considered to be significantly greater in this population)
Participants with known human immunodeficiency virus (HIV); due to lack of available safety data for eribulin therapy in HIV-infected participants
History of immunodeficiency including seropositivity for human immunodeficiency virus (HIV), or other acquired or congenital immune-deficient disease, or any active systemic viral infection requiring therapy (e.g., hepatitis B or C)
Human immunodeficiency virus (HIV)-positive patients are ineligible due to the risks associated with immune checkpoint blockade
Autoimmune disease requiring therapy, prior organ transplant, or human immunodeficiency virus (HIV) infection
Human immunodeficiency virus (HIV): negative HIV antibody / polymerase chain reaction (PCR)
Participants must have a negative human immunodeficiency virus (HIV) antibody/antigen test and negative Chlamydia (C.) trachomatis/Neisseria (N.) gonorrhea nucleic acid amplification test (NAAT)
Patient with human immunodeficiency virus (HIV) who require anti-viral or supportive care that interacts with the study drugs are not eligible
Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome. Anti-retroviral agents are known to have potential adverse pharmacokinetic interactions with nivolumab and/or BMS-813160. IN addition, patients not on anti-retroviral agents, regardless of HIV viral load, are at increased risk of lethal infections with marrow-suppressive therapy including chemotherapy. Testing for HIV must be performed at sites mandated by local requirements.
Known human immunodeficiency virus (HIV)-1 infection status, as documented by any nationally approved, licensed HIV rapid test performed in conjunction with screening (or enzyme-linked immunosorbent assay [ELISA], test kit, and confirmed by approved test at each study site; United States (U.S.) participants only: alternatively, this documentation may include a record demonstrating that another physician has documented the participant's HIV status based on either:\r\n* Approved diagnostic tests, or\r\n* The referring physician's written record that HIV infection was documented, with supporting information on the participant's relevant medical history and/or current management of HIV infection\r\n** Participants enrolled outside the U.S. must have a confirmatory diagnostic test sequence as appropriate per national standards, detailed as above, performed regardless of prior documented HIV status; for HIV-negative participants, testing must be performed no more than 1 month prior to study enrollment; NOTE: the term “licensed” refers to a U.S. Food and Drug Administration (FDA)-approved kit or for sites located in countries other than the United States, a kit that has been certified or licensed by an oversight body within that country and validated internally; WHO (World Health Organization) and CDC (Centers for Disease Control and Prevention) guidelines mandate that confirmation of the initial test result must use a test that is different from the one used for the initial assessment; a reactive initial rapid test should be confirmed by either another type of rapid assay or an enzyme/chemiluminescence immunoassay (E/CIA) that is based on a different antigen preparation and/or different test principle (e.g., indirect versus competitive), or a Western blot or a plasma HIV-1 ribonucleic acid (RNA) viral load
Known to be serologically positive for human immunodeficiency virus (HIV). Testing to determine possible infection status is not required.
No human immunodeficiency virus (HIV) infection; patients with immune dysfunction are at a significantly higher risk of toxicities from intensive immunosuppressive therapies
Patients with known human immunodeficiency virus (HIV), hepatitis B or C infections; testing to prove negative status is not required for enrollment unless it is deemed necessary for usual medical care of the patient
Patients with known human immunodeficiency virus (HIV) infection are eligible if being treated with non-interacting antiretroviral (ARV) agents or be willing to stop ARV for the protocol
Patients with human immunodeficiency virus (HIV) or hepatitis, or known active cytomegalovirus (CMV), Epstein–Barr virus (EBV) or any other viral illness requiring treatment are ineligible
History of immunodeficiency or autoimmune disease: patients with a history of immunodeficiency, including organ grafts and human immunodeficiency virus (HIV), will not be eligible
Patients with absolute lymphocyte count of < 500, who are known to be human immunodeficiency virus (HIV) positive, who have clinically significant active autoimmune disease, or are receiving immunosuppression following solid organ or stem cell transplant
Patients with a known confirmed diagnosis of human immunodeficiency virus (HIV) infection who are taking chronic anti-retroviral therapy (HAART) are ineligible if there is a potential for drug-drug interactions with the chemotherapeutic agents; patients with a known confirmed diagnosis of HIV infection who meet standard eligibility criteria and are not taking HAART with a potential for drug-drug interactions are eligible
Human immunodeficiency virus (HIV)-positive patients will be excluded unless antiretroviral therapy can be safely withheld during chemotherapy administration, based on clinical determination of infectious disease team evaluation
No human immunodeficiency virus (HIV) disease; patients with immune dysfunction are at a significantly higher risk of infection from intensive immunosuppressive therapies
Patients with known human immunodeficiency virus (HIV) infection are ineligible due to risk of pharmacokinetic interactions between anti-retroviral therapy and the study drugs, as well as potential for significant immunosuppression and serious infections with mTOR inhibition
Patient must have documentation of negative human immunodeficiency virus (HIV)-1 testing within 6 weeks prior to study registration (separate counseling and consent as per institutional guidelines)
Concomitant disease(s) that could prolong QT such as autonomic neuropathy (caused by diabetes, or Parkinson's disease), human immunodeficiency virus (HIV), cirrhosis, uncontrolled hypothyroidism or cardiac failure
Documentation of HIV infection at any time prior to study entry; documentation may be molecular (detectable viral ribonucleic acid [RNA] by polymerase chain reaction [PCR]), serologic (positive enzyme-linked immunosorbent assay [ELISA] and positive Western blot), or other federally approved licensed HIV test; prior documentation of HIV seropositivity is acceptable
Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) even if fully immunocompetent on ART—due to the unknown effects of HIV on the immune response to combined nivolumab plus ipilimumab or the unique toxicity spectrum of these drugs in patients with HIV
Patient must not be known to have human immunodeficiency virus (HIV) infection, active chronic hepatitis B or C, life-threatening illness unrelated to cancer, or any serious medical or psychiatric illness that could, in the investigator’s opinion, potentially interfere with participation in this study; patients will be tested for hepatitis B or C or HIV infection during screening if they are considered by the investigator to be at higher risk for these infections and have not been previously tested
Known HIV (HIV testing will be performed at screening if required by local regulations) in participants to be pretreated with obinutuzumab
Relevant diseases or clinical situations which may increase patient's risk: History of cardiac disease. Moderate breathing difficulties or oxygen requirement Active uncontrolled infection. Unhealed wound or presence of any external drainage. Chronically active viral hepatitis. Immunocompromised patients, including those known to be infected by human immunodeficiency virus (HIV). Known muscular disease or functional alteration
Has a congenital or acquired immunodeficiency, including subjects with known history of infection with human immunodeficiency virus (HIV) NOTE: HIV-positive subjects who are taking antiretroviral therapy are ineligible due to potential PK interactions with tazemetostat.
Patients with human immunodeficiency virus (HIV) infection are eligible, provided they meet the following:\r\n* No evidence of co-infection with hepatitis B or C\r\n* CD4+ cell count >= 400/mm^3\r\n* No evidence of resistant strains of HIV
Patients who are human immunodeficiency virus (HIV)+ (HIV+ patients registered at Fred Hutchinson Cancer Research Center [FHCRC] should be offered treatment on Protocol 1410)
Human papilloma virus-associated cancers\r\n* Histologically proven squamous carcinoma of the anal canal, penile, vaginal, vulva, or refractory cervical cancer with progression or intolerance to at least one treatment regimen including cisplatin or carboplatin will be enrolled; human papilloma virus (HPV) confirmation is not required\r\n* Patients must have metastatic disease not amenable to surgical resection\r\n* If human immunodeficiency virus (HIV)+ positive, all patients infected with human immunodeficiency virus (HIV) and CD4+ T cell count > 400 cells/mm^3 may be eligible for study\r\n* Patients co-infected with hepatitis B virus and/or hepatitis C virus may be included in this study provided that their liver function tests remain within the limits listed above; patients must be followed by a hepatologist during the course of this study
Known immunodeficiency or active HIV
Patients with human immunodeficiency virus (HIV) are eligible if their CD4 count is >= 350 cells/mm^3 and if they are not taking prohibited cytochrome (CYP)-interacting medications
Clinically significant autoimmune disorders or conditions of immunosuppression; patients with acquired immunodeficiency syndrome (AIDS) or human immunodeficiency virus (HIV)-1 associated complex or known to be HIV antibody seropositive or known to be recently polymerase chain reaction (PCR)+ for hepatitis B or C are not eligible for this study; the severely depressed or altered immune system found in these patients and the possibility of premature death would compromise study objectives
Clinically significant autoimmune disorders or conditions of immunosuppression; patients with AIDS or HIV-1 associated complex or known to HIV antibody seropositive or known to be recently PCR+ for hepatitis B or C virus are not eligible for this study; virology testing will be done within 6 months of T cell infusion; the severely depressed or altered immune system found in these patients and the possibility of premature death would compromise study objectives
Documented history of human immunodeficiency virus (HIV) positivity or other acquired immunodeficiency disorder, congenital immunodeficiency disorder, or history of organ transplantation
No uncontrolled infection\r\n* Note: infection is permitted if there is evidence of response to medication; eligibility of human immunodeficiency virus (HIV) infected patients will be determined on a case-by-case basis
Primary malignancy of the central nervous system or malignancies related to human immunodeficiency virus (HIV) or solid organ transplant.
Has a known diagnosis of immunodeficiency (human immunodeficiency virus [HIV] 1/2 antibodies) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment excluding steroids; attempts should be made to have patient on lowest possible dose of steroids
Known status of human immunodeficiency virus (HIV) which is not well-controlled at the time of study eligibility
Patient has known human immunodeficiency virus (HIV) or hepatitis B or C infection, as such patients may be at increased risk for toxicity due to concomitant treatment, and disease-related symptoms may preclude accurate assessment of the safety of PBI 05204.
All patients must be willing to undergo testing for human immunodeficiency virus (HIV) testing if not tested within the past 6 months
Have a known history of human immunodeficiency virus (HIV). Testing is not required in the absence of history.
Patients with a known confirmed diagnosis of human immunodeficiency virus (HIV) infection who are taking chronic anti-retroviral therapy (HAART) are ineligible if there is a potential for drug-drug interactions with the chemotherapeutic agents; patients with a known confirmed diagnosis of HIV infection who meet standard eligibility criteria and are not taking HAART with a potential for drug-drug interactions are eligible
Known history of infection with human immunodeficiency virus (HIV), based on medical history (screening laboratories [labs] to rule out HIV infection are not required)
Known human immunodeficiency virus (HIV) infected patients (HIV testing will not be performed as a part of screening) on combination antiretroviral therapy are eligible for inclusion; the use of zidovudine is not allowed
Known immunodeficiency or active HIV.
Serious concurrent medical illnesses (including uncontrolled major cardiac, pulmonary, Child-Pugh C liver or psychiatric diseases) or active major infections (including human immunodeficiency virus [HIV], hepatitis A-C)
Serologically positive human immunodeficiency virus (HIV) (testing required during screening)
Patients known to be human immunodeficiency virus (HIV) positive; HIV testing is not required in the absence of clinical signs and symptoms suggesting HIV infection
Known history of human immunodeficiency virus (HIV) or autoimmune diseases requiring immunosuppressant drugs
Participants known to be human immunodeficiency virus (HIV) positive; testing is not required in the absence of clinical signs and symptoms suggesting HIV infection
Human immunodeficiency virus (HIV)-positive patients or cancer survivors are eligible for this study if they fulfill all other eligibility criteria
Known human immunodeficiency virus (HIV)-positive individuals; high-dose ascorbate acid is a known cytochrome P450 3A4 (CYP450 3A4) inducer, which results in lower serum levels of antiretroviral drugs; a clinical trial designed to address these interaction issues is more appropriate than this phase 1 study
Hepatitis (Hep) B & C and human immunodeficiency virus (HIV)-infected patients, due to concerns in the ability to stimulate an effective immune response (determined by historical medical data)
No human immunodeficiency virus (HIV) infection; patients with a history of intravenous drug abuse or any behavior associated with an increased risk of HIV infection should be tested for exposure to the HIV virus; patients who test positive or who are known to be infected are not eligible; an HIV test is not required for entry on this protocol, but is required if the patient is perceived to be at risk
Known human immunodeficiency virus (HIV) positive patients; patients do not need to undergo specific screening for HIV to participate in this protocol, but those patients with known or documented infection of HIV are excluded
Patients with known human immunodeficiency virus (HIV) must have a CD4 count > 350 and be on concurrent antiretrovirals; patients with a history of intravenous drug abuse or any behavior associated with an increased risk of HIV infection should be tested for exposure to the HIV virus; an HIV test is not required for entry on this protocol, but is required if the patient is perceived to be at risk
Known history of HIV or underlying immunodeficiency
Human immunodeficiency virus (HIV) infection; there is theoretical concern that the degree of immune suppression associated with the treatment may result in progression of HIV infection
Severely compromised immunological state, including known human immunodeficiency virus (HIV)
Patients with human immunodeficiency virus (HIV)-associated primary central nervous system lymphoma are excluded
Human Immunodeficiency Virus (HIV) negative* * Status of HIV must be confirmed via a HIV antibody test or other confirmatory tests available within 12 months before screening or at screening
Serious concurrent illness or clinically-relevant active infection, including, but not limited to the following:\r\n* Known active hepatitis B or C (NOTE: testing is not required)\r\n* Known human immunodeficiency virus (HIV) infection (NOTE: testing is not required)\r\n* Varicella-zoster virus (shingles)\r\n* Cytomegalovirus infection\r\n* Any other known concurrent infectious disease, requiring IV antibiotics within 2 weeks of first dose of mirvetuximab soravtansine
Be self-reported to be immune-compromised (human immunodeficiency virus [HIV], chronic immunomodulators, chronic corticosteroids)
Subject has a known infection with hepatitis B or C, or history of human immunodeficiency virus (HIV) infection, or subject receiving immunosuppressive or myelosuppressive medications that would in the opinion of the investigator, increase the risk of serious neutropenic complications.
Patients with a history of immunodeficiency, including organ grafts and human immunodeficiency virus (HIV), will not be eligible
Severely compromised immunological state, including known human immunodeficiency virus (HIV)
Patients with any evidence of severe or uncontrolled systemic disease(s) including known cases of hepatitis B or C or human immunodeficiency virus (HIV); screening for chronic conditions is not required, although patients known to have such conditions at screening should not be included
Patients with known human immunodeficiency virus (HIV) or Hepatitis B or C (active, previously treated or both), a history of solid organ or bone marrow transplantation would generally be considered to have met exclusion criteria, however exceptions may be considered on a case-by-case basis by the medical monitor.
Known infection with human immunodeficiency virus (HIV) or subject has tested positive for HIV; patients without prior HIV testing will not be required to be tested
The patient is known to be positive for Human Immunodeficiency Virus (HIV) or has another confirmed or suspected immunosuppressive or immunodeficient condition (patients with thyroiditis are eligible)
Because of compromised cellular immunity and limited capacity to respond to vaccination, patients who are human immunodeficiency virus (HIV)+ will be excluded
Concomitant diseases/conditions: a) History of a clinically relevant cardiac condition c) Known chronic liver disease. d) Active uncontrolled infection. e) Known human immunodeficiency virus (HIV) infection. f) Limitation of the patient's ability to comply with the treatment or follow-up protocol.
No uncontrolled infection\r\n* Note: Infection is permitted if there is evidence of response to medication; eligibility of human immunodeficiency virus (HIV) infected patients will be determined on a case-by-case basis
Serologic evidence of HIV
History of human immunodeficiency virus (HIV) (protease inhibitors can have interaction with the SARM)
Patient has significant comorbidities (e.g., human immunodeficiency virus [HIV], transplant), or another illness that may require hospitalization
No uncontrolled infection\r\n* Note: infection is permitted if there is evidence of response to medication; eligibility of human immunodeficiency virus (HIV) infected patients will be determined on a case?by?case basis
Patients report a history of peripheral vascular disease, diabetes, vitamin B12 deficiency, thyroid dysfunction, human immunodeficiency virus (HIV) neuropathy, cervical or lumbar pain with radiculopathy, or another painful condition that is difficult for them to distinguish from their CIN
Subjects with active uncontrolled infection or who are human immunodeficiency virus (HIV) positive (subjects with acute infections requiring treatment should delay screening/enrollment until the course of therapy has been completed and the event is considered controlled)
Known history of human immunodeficiency virus (HIV). Subjects should be tested for HIV prior to Randomization if required by local regulations or EC;
HIV positive; documentation of HIV-1 infection by means of any one of the following:\r\n* Documentation of HIV diagnosis in the medical record by a licensed health care provider;\r\n* Documentation of receipt of antiretroviral therapy (ART) by a licensed health care provider (documentation may be a record of an ART prescription in the participant’s medical record, a written prescription in the name of the participant for ART, or pill bottles for ART with a label showing the participant’s name; receipt of at least two agents is required; each component agent of a multi-class combination ART regimen will be counted toward the 2-agent requirement, excepting receipt of a pre-exposure prophylaxis [PrEP] regimen alone [e.g., Truvada], which is exclusionary);\r\n* HIV-1 ribonucleic acid (RNA) detection by a licensed HIV-1 RNA assay demonstrating > 1000 RNA copies/mL\r\n* Any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV-1 western blot confirmation or HIV rapid multispot antibody differentiation assay\r\n** NOTE: A “licensed” assay refers to a United States (U.S.) Food and Drug Administration (FDA)-approved assay, which is required for all investigational new drug (IND) studies
Patients who receive maraviroc for the treatment of human immunodeficiency virus (HIV) infection
Human immunodeficiency virus (HIV) infection; patients should provide consent for HIV testing according to the institution's standard practice
History of diabetic neuropathy or neuropathy related to human immunodeficiency virus (HIV)
History of diabetic neuropathy or neuropathy related to human immunodeficiency virus (HIV)
Males who self-identify as having had or currently having sex with men; both human immunodeficiency virus (HIV)-infected and HIV-uninfected subjects are being enrolled
Men with human immunodeficiency virus (HIV) and/or prior anal disease will be included given their increased risk for current disease
HIV positive; documentation of HIV-1 infection by means of any one of the following:\r\n* Documentation of HIV diagnosis in the medical record by a licensed health care provider;\r\n* Documentation of receipt of antiretroviral therapy (ART) by a licensed health care provider (documentation may be a record of an ART prescription in the participant’s medical record, a written prescription in the name of the participant for ART, or pill bottles for ART with a label showing the participant’s name; receipt of at least two agents is required; each component agent of a multi-class combination ART regimen will be counted toward the 2-agent requirement, excepting receipt of a pre-exposure prophylaxis [PrEP] regimen alone [e.g., Truvada], which is exclusionary);\r\n* HIV-1 ribonucleic acid (RNA) detection by a licensed HIV-1 RNA assay demonstrating > 1000 RNA copies/mL;\r\n* Any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV-1 western blot confirmation or HIV rapid multispot antibody differentiation assay\r\n* NOTE: A “licensed” assay refers to a United States (US) Food and Drug Administration (FDA)-approved assay, which is required for all investigational new drug (IND) studies
Participants with a known diagnosis of human immunodeficiency virus (HIV); Note: an HIV screening test does not have to be performed to evaluate this criterion
Known diagnosis of human immunodeficiency virus (HIV); Note: An HIV screening test does not have to be performed to evaluate this criterion
No human immunodeficiency virus (HIV) disease (patients with immune dysfunction are at a significantly higher risk of infection from intensive immunosuppressive therapies)
Documented human immunodeficiency virus (HIV) infection, genital warts, chancroid, or pelvic inflammatory disease that will require long term treatment
Acquired immunosuppressive diseases such as active human immunodeficiency virus (HIV) infection or congenital diseases of immunity
HIV-1 infection as documented by any federally approved, licensed HIV test performed in conjunction with screening (enzyme linked immunosorbent assay [ELISA], Western blot or other approved test); alternatively, this documentation may include a record that another physician has documented that the patient has HIV based on prior ELISA and western blot, or other approved diagnostic tests; if the participant’s HIV status is documented by an outside physician, the protocol team strongly recommends obtaining a copy of the HIV laboratory reports from this physician; all confirmatory tests and the physician’s note must be on file before the participant is enrolled; in the rare circumstance where only an outside physician’s note with no supporting laboratory documentation is available, the local site should have additional tests performed to verify the participant’s HIV status; one of the following additional tests should be performed:\r\n* A rapid HIV test\r\n* ELISA and Western blot\r\n* Chemiluminescence immunoassay and Western blot\r\n* HIV ribonucleic acid (RNA) > 2000 copies/mL\r\n* HIV antigen test
Known human immunodeficiency virus (HIV) positive patients due to the previous toxicity noted with [18F] FLT in this patient group
Patients who are known to be human immunodeficiency virus (HIV)-positive will be excluded as highly active antiretroviral therapy (HAART) and HIV itself are known to cause peripheral neuropathy
Patients with newly diagnosed, relapsed, or refractory EBV-associated or KSHV-associated malignancies including human immunodeficiency virus (HIV)-associated lymphomas are potentially eligible
The patient is known to be positive for the human immunodeficiency virus (HIV). The effect of BPM31510 on HIV medications is unknown. Note: HIV testing is not required for eligibility, but if performed previously and was positive, the patient is ineligible for the study.
The subject is human immunodeficiency virus (HIV) positive
Patients that are known to be positive for human immunodeficiency virus (HIV) are not eligible; note: inclusion of HIV positive patients will be considered at a later date
The patient must NOT have a known positive test for human immunodeficiency virus (HIV); patients do not need to be screened for HIV; patients with HIV are excluded
Human immunodeficiency virus (HIV) positive patients
Human Immunodeficiency Virus (HIV) positive
Positive human immunodeficiency virus (HIV) status.
Patients who are human immunodeficiency virus (HIV) positive on highly active anti-retroviral therapy (HAART) will be excluded from the study
Patients known to be human immunodeficiency (HIV)-positive receiving anti-retroviral therapy are excluded from the study
Patients who are serologically positive for human immunodeficiency virus (HIV)
Positive for human immunodeficiency virus (HIV)
Human immunodeficiency virus (HIV)-positive
Human immunodeficiency virus (HIV)-positive patients are NOT excluded from the study
Human immunodeficiency virus (HIV)-positive patients receiving anti-retroviral therapy are excluded from this study; HIV positive patients not receiving antiretroviral therapy are excluded
Patients who are human immunodeficiency virus positive (HIV+)
Subjects who have tested positive for human immunodeficiency virus (HIV)
Patients who are positive for human immunodeficiency virus (HIV)
DONOR: Human immunodeficiency virus (HIV) positive
Positive human immunodeficiency virus (HIV) antibody at Screening
Human immunodeficiency virus (HIV) positive subjects are excluded
Human immunodeficiency virus (HIV) positive patients
Human immunodeficiency virus (HIV)-positive patients are ineligible
Known human immunodeficiency virus (HIV)-positive participants (even if on combination retrovirals, participant will be excluded)
Human immunodeficiency virus (HIV)-positive patients receiving anti-retroviral therapy are excluded from this study
Positive human immunodeficiency virus (HIV) status
Human immunodeficiency virus (HIV)-positive patients receiving anti-retroviral therapy are excluded from this study; HIV positive patients not receiving antiretroviral therapy are excluded
Human immunodeficiency virus (HIV) positive
Human immunodeficiency virus (HIV) positive
Is human immunodeficiency virus (HIV) positive
Know to be human immunodeficiency virus (HIV) positive
Patients known to be human immunodeficiency virus (HIV) positive who are not receiving anti-retroviral therapy will be excluded
Has a known history of human immunodeficiency virus (HIV); HIV-positive patients receiving anti-retroviral therapy are excluded from this study; HIV positive patients not receiving antiretroviral therapy are excluded
Patients can be human immunodeficiency virus (HIV) positive or negative
Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded from the study
Human immunodeficiency virus (HIV) positive
Because patients with immune deficiency are not expected to respond to this therapy, human immunodeficiency virus (HIV)-positive patients are excluded from the study
Human immunodeficiency virus (HIV) positive patients are ineligible
HIV1 (human immunodeficiency virus-1) or HIV2 positive
DONOR: Human immunodeficiency virus (HIV) positive
HIV1 (human immunodeficiency virus-1) or HIV2 positive
Known human immunodeficiency virus (HIV)-positive patients are excluded from the study; for patients receiving combination anti-retroviral therapy; screening for HIV status will not be performed
Human immunodeficiency virus (HIV)-positive patients
Human immunodeficiency virus (HIV)-positive
Human immunodeficiency virus (HIV) positive
Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded
Human immunodeficiency virus (HIV)-positive patients are excluded
Positive human immunodeficiency virus antibody
Human immunodeficiency virus (HIV) positive
Human immunodeficiency virus (HIV) positive
Human immunodeficiency virus (HIV) positive
Human immunodeficiency virus (HIV)-positive patients are excluded from the study
Patient who is human immunodeficiency virus (HIV)-positive
Patient is human immunodeficiency virus (HIV)-positive
2nd BMT, human immunodeficiency virus (HIV)-1 positive
Human immunodeficiency virus (HIV)-positive
Positive human immunodeficiency virus (HIV) antibody at Screening
Human immunodeficiency virus (HIV) infected patients (defined as HIV-1/HIV-2 antibody positive).
Human immunodeficiency virus (HIV) positive
Known human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded from the study
Human immunodeficiency virus (HIV)-positive patients
Positive for human immunodeficiency virus (HIV)
Patients who are positive for human immunodeficiency virus type 1 (HIV-1) and are receiving combination anti-retroviral therapy
Patients who are human immunodeficiency virus positive (HIV+) will be excluded
Human immunodeficiency virus (HIV) positive patients will be excluded
Human immunodeficiency virus (HIV)-positive patients
Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded from the study
Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded from the study; note: HIV testing is not required for entry into this protocol
Human immunodeficiency virus (HIV)-positive patients are excluded from this study
Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded from the study
Human immunodeficiency virus (HIV)-positive patients and those with other acquired/inherited immunodeficiency
Human immunodeficiency virus (HIV) positive
Human immunodeficiency virus (HIV)-positive subjects are excluded from the study
Patients who are positive for human immunodeficiency virus (HIV)
Human immunodeficiency virus (HIV)-positive
Patients known to be human immunodeficiency virus (HIV) positive and receiving highly active anti-retroviral therapy (HAART)
Human immunodeficiency virus (HIV) positive patients
Positive for Human Immunodeficiency Virus (HIV).
Subjects positive for Human Immunodeficiency Virus (HIV)
Human immunodeficiency virus (HIV) positive
Human immunodeficiency virus (HIV) negative or positive
Known human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded from the study
EXCLUSION CRITERIA FOR TRANSPLANT PHASE: Human immunodeficiency virus (HIV)-positive
Human immunodeficiency virus (HIV) positive patients or hepatitis B or C positive patients
Human immunodeficiency virus (HIV)-positive
Human immunodeficiency virus (HIV)-positive patients
Human immunodeficiency virus (HIV) positive patients
Participant has tested positive for human immunodeficiency virus (HIV).
Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded from the study; note: HIV testing is not required for entry into this protocol
Human Immunodeficiency virus (HIV) positive
Human immunodeficiency virus (HIV) positive
Human immunodeficiency virus (HIV)-positive patients are excluded
Patients who are human immunodeficiency virus positive (HIV+)
Subject has tested positive for human immunodeficiency virus (HIV).
Human immunodeficiency virus (HIV)-positive patients are excluded
Human immunodeficiency virus (HIV) positive patients are not eligible for this protocol; hepatitis B and C positive patients will be evaluated on a case-by-case basis
Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy
Human immunodeficiency virus (HIV) positive
Human immunodeficiency virus (HIV) positive patients
Human immunodeficiency virus (HIV) positive
Human immunodeficiency virus (HIV) positive (highly immunosuppressive treatment)
Patients who are serologically true-positive for human immunodeficiency virus (HIV)
Patients who are human immunodeficiency virus (HIV) positive
Human immunodeficiency virus (HIV) positive
Positive human immunodeficiency virus (HIV) infection at screening
Human immunodeficiency virus (HIV)-positive patients
Human immunodeficiency virus (HIV) positive
Human immunodeficiency virus (HIV) positive
Human immunodeficiency virus (HIV)-positive patients are ineligible
Positive for human immunodeficiency virus (HIV) infection
Human immunodeficiency virus (HIV) positive patients will be excluded
Human immunodeficiency virus-positive patients receiving combination anti-retroviral therapy are excluded from the study
Human immunodeficiency virus (HIV) positive patients who are not on retroviral therapy will not be excluded from cohort 1, the normal liver function cohort\r\n* HIV positive patients who are not on retroviral therapy will be excluded from cohorts 2-4
A history of human immunodeficiency virus (HIV) antibody positive or tests positive for HIV if tested at screening
Human immunodeficiency virus (HIV) positive
Human immunodeficiency virus (HIV)-positive patients receiving anti-retroviral therapy are excluded from this study
Human immunodeficiency virus (HIV)-positive patients are ineligible
Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded
Human immunodeficiency virus (HIV) positive patients are not eligible
Human immunodeficiency virus (HIV) - positive participants receiving anti-retroviral therapy
Positive for presence of human immunodeficiency virus type 1 or 2 (HIV 1 and HIV 2).
Patients who are human immunodeficiency virus (HIV)-positive are excluded from the study
Human immunodeficiency virus (HIV)-positive patients receiving anti-retroviral therapy are excluded from this study; HIV positive patients not receiving antiretroviral therapy are excluded
Known human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded from the study
Known human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded from the study
Human immunodeficiency virus (HIV)-positive patients on antiretroviral therapy are excluded from the study
Human immunodeficiency virus (HIV)-positive status
HIV1 (human immunodeficiency virus-1) or HIV2 positive
Human immunodeficiency virus (HIV)-positive participants are ineligible
Patients who are known to be serologically positive for human immunodeficiency virus (HIV) and are receiving antiviral therapy
Be human immunodeficiency virus (HIV)-positive
Human immunodeficiency virus (HIV)-positive participants are excluded
Human immunodeficiency virus (HIV)-positive patients are ineligible
Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded from the study
Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies).
Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
Has a known history of Human Immunodeficiency Virus (HIV) (positive for HIV p24 antigen or HIV 1/2 antibodies)
Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies) infection
COHORT 1: Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
COHORT 2: Has a known history of HIV (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Known Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies) disease.
Patients who have a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies) are not eligible
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Known history of human immunodeficiency virus [(HIV) HIV 1/2 antibodies].
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV or HIV 1/2 antibodies); testing not required
Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies).
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies).
Known history of human immunodeficiency virus (HIV) (HIV1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies) disease
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies).
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies).
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies).
Has a known history of human immunodeficiency virus (HIV)(HIV 1/2 antibodies)
Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV ½ antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Known history of human immunodeficiency virus (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Patients with a known history of antibodies to human immunodeficiency virus (HIV) -1 or -2 are not eligible. Patients with live vaccines
Has a history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Known carriers of HIV antibodies
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Known active human immunodeficiency virus (HIV1/2 antibodies)
Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies, testing not mandatory)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Subject has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies) as determined by medical record review
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Patient has known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies) or active hepatitis
Has a known history of human immunodeficiency virus (HIV) infection (HIV 1/2 antibodies); patients with treated HIV, as evidenced by stable CD4 > 200 for at least 6 months, are eligible
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Known history of human immunodeficiency virus (HIV) infection (HIV 1/2 antibodies).
Known history of HIV (HIV 1/2 antibodies).
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies). Testing not required.
Patient has known history of human immunodeficiency virus (HIV) (HIV ½ antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies).
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies)
Has known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
History of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Known history of human immunodeficiency virus (HIV; HIV 1/2 antibodies).
Has a known history of HIV (HIV 1/2 antibodies).
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Known history of human immunodeficiency virus [(HIV) HIV 1/2 antibodies].
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies); testing not required
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies); Note: testing not required at baseline unless clinically indicated
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies)
Has known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Known history of human immunodeficiency virus (HIV); HIV 1/2 antibodies.
Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
No known evidence of human immunodeficiency virus (HIV) infection
Patients with known human immunodeficiency virus (HIV) infection
A known history of human immunodeficiency virus (HIV)
Patient has a known history of human immunodeficiency virus (HIV) infection (testing not mandatory)
Known human immunodeficiency virus (HIV) infection
Patients with a known human immunodeficiency virus (HIV) infection are not eligible (HIV testing not required)
Patients with known infection with human immunodeficiency virus (HIV) will not be eligible
Patients with known human immunodeficiency virus (HIV) infection are NOT eligible for participation
Known diagnosis of human immunodeficiency virus (HIV) infection.
Has a known history of human immunodeficiency virus (HIV) infection.
Known human immunodeficiency virus (HIV) patients with active and untreated disease
Known human immunodeficiency virus (HIV) infection
Known human immunodeficiency virus (HIV) infection
Known diagnosis of human immunodeficiency virus (HIV); (HIV testing is not required)
Known history of human immunodeficiency virus (HIV) infection
Known history of human immunodeficiency virus (HIV)
Known history of Human Immunodeficiency Virus (HIV) infection
Known human immunodeficiency virus (HIV) infection
Patient has a known history of human immunodeficiency virus (HIV) infection (testing is not required)
Patient has a known history of human immunodeficiency virus (HIV) infection (testing not required)
Patients with a known human immunodeficiency (HIV) infection are not eligible
Known human immunodeficiency virus (HIV) infection
Known infection with human immunodeficiency virus (HIV)
Individuals with known human immunodeficiency virus (HIV) infection are excluded from this study
Known human immunodeficiency virus (HIV) infection
Known history of human immunodeficiency virus (HIV) infection
Patients must not have known human immunodeficiency virus (HIV) infection
Known active human immunodeficiency virus (HIV)
Known human immunodeficiency (HIV) virus infection.
Has a known history of human immunodeficiency virus (HIV) infection.
Has a known history of human immunodeficiency virus (HIV) infection
Has a known history of human immunodeficiency virus (HIV) infection.
Has a known history of human immunodeficiency virus (HIV) infection
Known history of human immunodeficiency virus (HIV)
Patient has a known history of human immunodeficiency virus (HIV) infection (testing not mandatory)
Known history of Human Immunodeficiency Virus (HIV)
Known history of human immunodeficiency virus infection (HIV)
Participant has a known infection with human immunodeficiency virus (HIV).
Known human immunodeficiency virus (HIV) infection
Have a known human immunodeficiency virus (HIV) infection or known activated/reactivated hepatitis A, B, or C.
Has known history of Human Immunodeficiency Virus (HIV).
Known human immunodeficiency virus (HIV).
Patients with known human immunodeficiency virus (HIV) are excluded
Known Human Immunodeficiency Virus (HIV)
Known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing is not mandatory)
Known human immunodeficiency virus (HIV) infection
Known human immunodeficiency virus (HIV) or other history of immunodeficiency disorder
Known active human immunodeficiency virus (HIV)
Known human immunodeficiency virus (HIV) infection
Has a known history of human immunodeficiency virus (HIV)
Known infection with the human immunodeficiency virus (HIV) virus
Known human immunodeficiency virus (HIV) infection
Known history of infection with human immunodeficiency virus (HIV)
Patients with known human immunodeficiency virus (HIV) infection or are not eligible
Has a known history of human immunodeficiency virus (HIV) infection
Has a known history of human immunodeficiency virus (HIV) infection.
Known or suspected human immunodeficiency virus (HIV) infection
Has a known history of human immunodeficiency virus (HIV) infection
Known human immunodeficiency virus (HIV) infection
Known human immunodeficiency virus (HIV) infection
Known human immunodeficiency virus (HIV) infection
Known human immunodeficiency virus (HIV) infection
FOR ALL PHASES (Ib AND II): Known history of human immunodeficiency virus (HIV) infection
Patients with known human immunodeficiency virus (HIV)
Known human immunodeficiency virus (HIV) infection (HIV testing is not required as part of this study)
Known to be human immunodeficiency virus (HIV)+
Patients with known human immunodeficiency virus (HIV) infection, or hepatic insufficiency
Known known human immunodeficiency virus (HIV) infection
Known history of human immunodeficiency virus (HIV) disease
Known history of human immunodeficiency virus (HIV) infection
Patient has a known history of human immunodeficiency virus (HIV) infection (testing not mandatory)
Known history of human immunodeficiency virus (HIV) infection
Has a known history of human immunodeficiency virus (HIV).
Known human immunodeficiency virus (HIV) infection
Known infection with human immunodeficiency virus (HIV)
Patients with known human immunodeficiency virus (HIV) infection are not eligible
Known human immunodeficiency virus (HIV) infection
Subjects with known human immunodeficiency virus (HIV) infection
Patients with a known human immunodeficiency virus (HIV) diagnosis are excluded from the study
Known human immunodeficiency virus (HIV) infection
Known history of human immunodeficiency virus (HIV) infection
Known history of human immunodeficiency virus (HIV) infection
Known Human immunodeficiency virus (HIV) infection;
Known human immunodeficiency virus (HIV) infection
Has a known history of Human Immunodeficiency Virus (HIV) infection
Known human immunodeficiency virus (HIV)
Is immunocompromised (i.e. has congenital immunodeficiency), including subjects known history of infection with human immunodeficiency virus (HIV)
Known human immunodeficiency virus (HIV) infection
Patients must not have known human immunodeficiency virus (HIV) infection
Patients with known human immunodeficiency virus (HIV) infection
Known human immunodeficiency virus (HIV) infection
Known diagnosis of human immunodeficiency virus (HIV) infection
Has a known history of human immunodeficiency virus (HIV)
Patients with known human immunodeficiency virus (HIV) are ineligible for this study
Known history of human immunodeficiency virus (HIV) infection
Patients with known human immunodeficiency virus (HIV) infection
Known diagnosis of human immunodeficiency virus (HIV) infection
Known diagnosis of human immunodeficiency virus (HIV) infection
Known human immunodeficiency virus (HIV) infection
Known history of human immunodeficiency virus (HIV)
Known diagnosis of human immunodeficiency virus (HIV) infection (please note that HIV testing is not mandatory)
Patients with known human immunodeficiency virus (HIV) infection
Patients with known human immunodeficiency virus (HIV) infection
Known human immunodeficiency virus (HIV) infection
Patients with known human immunodeficiency virus (HIV) infection
Known history of Human Immunodeficiency Virus (HIV)
Has a known history of Human Immunodeficiency Virus (HIV).
Known human immunodeficiency virus (HIV) infection
Has known human immunodeficiency virus (HIV) infection.
Patients with a known human immunodeficiency virus (HIV) infection are NOT eligible for participation
Known diagnosis of human immunodeficiency virus (HIV) infection
Patients with known human immunodeficiency virus (HIV) are NOT eligible for the study
Known Human Immunodeficiency Virus (HIV) infection.
211 Known infection with human immunodeficiency virus (HIV).
Has a known history of human immunodeficiency virus (HIV) infection
Known history of human immunodeficiency virus (HIV) infection.
Known infection with the human immunodeficiency (HIV) virus
Known history of infection with human immunodeficiency virus (HIV)
Known infection with human immunodeficiency virus (HIV)
Patients with known human immunodeficiency virus (HIV) infection
Patients with known human immunodeficiency virus (HIV) infection
Known history of human immunodeficiency virus (HIV) infection
Known history of human immunodeficiency virus (HIV)
Known human immunodeficiency virus (HIV) infection
Known history of Human Immunodeficiency Virus (HIV) infection.
Patients with known human immunodeficiency virus (HIV) infection are excluded
ARM A: Known human immunodeficiency virus (HIV) infection
Known human immunodeficiency virus (HIV) infection
Subjects with known human immunodeficiency virus (HIV) infection
No known human immunodeficiency virus (HIV) infection
Has a known history of human immunodeficiency virus (HIV)
Patients with known history of human immunodeficiency virus (HIV)
Known history of human immunodeficiency virus (HIV)
Patient has a known history of human immunodeficiency virus (HIV) infection (testing not mandatory)
Patient has a known history of human immunodeficiency virus (HIV) infection
Known human immunodeficiency virus (HIV) infection
Known human immunodeficiency virus (HIV) infection (pre-study testing not required)
Patient has a known history of human immunodeficiency virus (HIV) infection (testing not mandatory)
Known history of human immunodeficiency virus (HIV)
Subject has a known history of human immunodeficiency virus (HIV) infection (testing not mandatory)
Patients who have known human immunodeficiency virus (HIV) or an uncontrolled infection are not eligible
Patients with known human immunodeficiency virus (HIV) infection are ineligible
Known human immunodeficiency virus (HIV) or other history of immunodeficiency disorder
Patients with known human immunodeficiency virus (HIV) infection
Known diagnosis of human immunodeficiency virus (HIV) infection
Any other pre-existing immunodeficiency condition (including known human immunodeficiency virus [HIV] infection)
Patients must not have known human immunodeficiency virus (HIV) infection
Patients with active infections or known infection with human immunodeficiency virus (HIV)
Known human immunodeficiency virus (HIV) disease
Known human immunodeficiency virus (HIV) disease
Has a known history of human immunodeficiency virus (HIV).
Has a known history of Human Immunodeficiency Virus (HIV)
Known history of human immunodeficiency virus (HIV)
Has a known history of human immunodeficiency virus (HIV).
Has a known history of Human Immunodeficiency Virus (HIV) infection.
Known human immunodeficiency virus (HIV) infection
Has known history of Human Immunodeficiency Virus (HIV).
Has a known history of Human Immunodeficiency Virus (HIV).
Known Human Immunodeficiency Virus (HIV) infection
Patients with a known history of human immunodeficiency virus (HIV) must not be on active treatment for HIV
Known history of human immunodeficiency virus (HIV)
Have a known history of human immunodeficiency virus (HIV) infection.
Known human immunodeficiency virus (HIV) infection.
Known Human immunodeficiency virus (HIV) infection.
Known human immunodeficiency virus (HIV) infection
Has a known history of human immunodeficiency virus (HIV)
Has a known history of Human Immunodeficiency Virus (HIV)
Patients with known human immunodeficiency virus (HIV) infection must have CD4 count greater than 200
Patients with known human immunodeficiency virus (HIV) infection.
Known history of human immunodeficiency virus (HIV)
Known history of human immunodeficiency virus (HIV)
Patients must have no known human immunodeficiency virus (HIV) infection
Known human immunodeficiency virus (HIV) disease
Patient has a known diagnosis of human immunodeficiency virus (HIV) infection
Patient has a known history of human immunodeficiency virus (HIV) infection (testing is not mandatory)
Patients with a known diagnosis of human immunodeficiency virus (HIV) infection.
Patient has a known history of human immunodeficiency virus (HIV) infection (testing not mandatory).
Known to be human immunodeficiency virus (HIV)+
Current known active infection with human immunodeficiency virus (HIV)
Patient with known history of human immunodeficiency virus (HIV), or any uncontrolled active systemic infection
Known human immunodeficiency virus (HIV) infection
Known history of Human Immunodeficiency Virus (HIV) infection
Participant has a known history or current diagnosis of human immunodeficiency virus (HIV) infection, regardless of treatment status.
Subjects with known human immunodeficiency virus (HIV) infection
Known human immunodeficiency virus (HIV) infection
Known history of human immunodeficiency virus (HIV)
Has a known history of Human Immunodeficiency Virus (HIV)
Known prior history of human immunodeficiency virus (HIV)
Known infection with the human immunodeficiency virus (HIV) virus
Known human immunodeficiency virus (HIV) infection
Known history of human immunodeficiency virus (HIV)
Known history of human immunodeficiency virus (HIV) infection.
Known history of human immunodeficiency virus (HIV)
Known human immunodeficiency virus (HIV)
Patient is known to have human immunodeficiency virus (HIV) infection
Known diagnosis of human immunodeficiency virus (HIV) infection
Known human immunodeficiency virus (HIV) infection
Known history of human immunodeficiency virus (HIV)
No known human immunodeficiency virus (HIV) infection
Known HIV (Human Immunodeficiency Virus) infection.
The patient has a known history or current diagnosis of human immunodeficiency virus (HIV) infection, regardless of treatment status.
Patients with known human immunodeficiency virus (HIV) infection, or hepatic insufficiency
Has known history of human immunodeficiency virus (HIV) infection
Patients with known human immunodeficiency virus (HIV) infection
Patients must have no known history of human immunodeficiency virus (HIV)
Known human immunodeficiency virus (HIV) infection
Known human immunodeficiency virus (HIV) infection
Known history of human immunodeficiency virus (HIV) infection
Patients with known human immunodeficiency virus (HIV) infection
Patients with known human immunodeficiency virus (HIV) infection
Known human immunodeficiency virus (HIV) infection
Known human immunodeficiency virus (HIV) infection
Known diagnosis of human immunodeficiency virus (HIV) infection
Known human immunodeficiency virus (HIV) infection
Patients with known human immunodeficiency virus (HIV) are excluded
Known infection with human immunodeficiency virus (HIV)
Known human immunodeficiency virus (HIV) infection
Known diagnosis of human immunodeficiency virus (HIV) infection
Known history of human immunodeficiency virus (HIV) infection
Known human immunodeficiency virus (HIV) infection
Known uncontrolled human immunodeficiency virus (HIV) infection
Has a known history of human immunodeficiency virus (HIV) infection
Patients with a known diagnosis of human immunodeficiency virus (HIV) infection.
Has a known history of Human Immunodeficiency Virus (HIV).
Patients who have a known history of human immunodeficiency virus (HIV) will be excluded
Patient with known diagnosis of human immunodeficiency virus (HIV) infection
Known history of human immunodeficiency virus (HIV)
Known infection with human immunodeficiency virus (HIV)
Subject is known to have human immunodeficiency virus (HIV) infection.
Known history of human immunodeficiency virus (HIV) infection
Known history of human immunodeficiency virus (HIV) type 1/2 or other immunodeficiency disease
Known human immunodeficiency viral (HIV) infection
Known diagnosis of human immunodeficiency virus (HIV) infection (testing is not mandatory).
Known diagnosis of human immunodeficiency virus (HIV) infection (testing is not mandatory).
Known human immunodeficiency virus (HIV) infection
Known infection with human immunodeficiency virus (HIV).
Patient has known infection with human immunodeficiency virus (HIV)
Patient has known infection with human immunodeficiency virus (HIV)
Known human immunodeficiency virus (HIV) infection
Known infection with human immunodeficiency virus (HIV)
Known human immunodeficiency virus (HIV) infection
Known history of human immunodeficiency virus (HIV) infection
Has known human immunodeficiency virus (HIV) infection;
Known active or chronic infection with human immunodeficiency virus (HIV)
Known history of human immunodeficiency virus (HIV) infection
Known human immunodeficiency virus (HIV) infection
Known chronic infection with human immunodeficiency virus (HIV)
Known human immunodeficiency virus (HIV) infection
Known human immunodeficiency virus (HIV) infection
Known diagnosis of human immunodeficiency virus (HIV) infection; testing is not required for participation
Known human immunodeficiency virus (HIV) infection
Known human immunodeficiency virus (HIV) infection
Known human immunodeficiency virus (HIV) infection
Known diagnosis of human immunodeficiency virus (HIV) infection
Known human immunodeficiency virus (HIV) infection
Known human immunodeficiency virus (HIV) infection
Known human immunodeficiency virus (HIV) infection
Known human immunodeficiency virus (HIV) infection; testing prior to enrollment is not required
Patient has a known history of human immunodeficiency virus (HIV) infection (testing not mandatory) infection
Known human immunodeficiency virus (HIV)-related malignancy.
Known human immunodeficiency virus (HIV) infection (pre-study testing not required)
Has known history of Human Immunodeficiency Virus (HIV)
Known human immunodeficiency virus (HIV)-related malignancy.
Known human immunodeficiency syndrome (HIV)
Has a known history of human immunodeficiency virus (HIV)
Patients with known human immunodeficiency virus (HIV) will be excluded
Patient is known to have human immunodeficiency virus (HIV) infection
Known infection with human immunodeficiency virus (HIV)
Known human immunodeficiency virus (HIV) infection based on history
Known human immunodeficiency virus (HIV)
Known human immunodeficiency virus (HIV) infection
Has a known history of human immunodeficiency virus (HIV) infection.
Known human immunodeficiency virus (HIV) infection
Known human immunodeficiency virus (HIV) infection (HIV testing not required)
Known human immunodeficiency virus (HIV) infection.
Known human immunodeficiency virus (HIV) disease.
Has a known history of human immunodeficiency virus (HIV).
Known or suspected human immunodeficiency virus (HIV) infection.
Has a known history of human immunodeficiency virus (HIV)
Known history of infection with human immunodeficiency virus (HIV)
HIV-1 infection, as documented by any federally approved, licensed HIV rapid test performed in conjunction with screening (or enzyme linked immunosorbent assay [ELISA], test kit, and confirmed by Western blot or other approved test); alternatively, this documentation may include a record demonstrating that another physician has documented the participant's HIV status based on either: 1) approved diagnostic tests, or 2) the referring physician's written record that HIV infection was documented, with supporting information on the participant’s relevant medical history and/or current management of HIV infection
Known history of HIV infection
HIV infection.
HIV-1 infection, as documented by any federally approved, licensed HIV rapid test performed in conjunction with screening (or enzyme linked immunosorbent assay [ELISA], test kit, and confirmed by western blot or other approved test); alternatively, this documentation may include a record demonstrating that another physician has documented the participant's HIV status based on either: 1) approved diagnostic tests, or 2) the referring physician's written record that HIV infection was documented, with supporting information on the participant's relevant medical history and/or current management of HIV infection
HIV infection
Known history of HIV.
A known history of HIV
EXCLUSION - TREATMENT: Active infection with HIV or HTLV
Has known HIV
Known positiv test for HIV
DONOR: Infection with HIV
Known HIV infection.
Known HIV infection.
Patients with documented immunodeficiency such as HIV infection.
TREATMENT WITH SJCAR19: History of HIV infection
Known history of HIV
Subjects with significant history of systemic immunosuppression due to drugs or infection with HIV or HTLV 1.
HIV infection
Known history of HIV infection (testing not mandatory).
Any HIV status
Known HIV-infected patients
PART 2: History of HIV infection
Patients with known HIV disease
Known history of HIV infection.
Any HIV status
HIV infection
Patients with a known history of HIV.
HIV infection or a known HIV-related malignancy.
Subject has known HIV infection
Known to be HIV+
History of HIV infection.
Known HIV infection.
Known infection with HIV (testing of patients not known to be infected with HIV is not required prior to study entry)
ARM B: Known HIV infection
HIV infection
Known history of infection with HIV.
Known history of infection with HIV.
HIV negative
Subjects with known HIV infection
HIV infection
HIV related disease or known or suspected HIV+
Subjects with HIV infection.
HIV.
Subjects with documentation of confirmed HIV-1 infection (i.e. HIV-positive), and a hematologic malignancy who meets all other eligibility requirements must:
Known HIV infection.
Known history of HIV infection. Testing for HIV status is not necessary unless clinically indicated
HIV or HTLV infection
Subjects with uncontrolled human immunodeficiency virus (HIV) are not eligible; controlled HIV is defined as a CD4 count > institutional lower limit of normal and no current co-infection; uncontrolled HIV is all other HIV infection; note that patients with controlled infection should be allowed to participate only if they are not receiving prohibited cytochrome P450 (CYP) interactive medications
Known carrier of HIV.
Known HIV carrier
Known infection with HIV
HIV infection.
Known HIV infection;
Patients with treated HLTV or HIV
History of HIV infection.
Prior history of HIV-positivity (routine HIV testing is not required pre-treatment)
HIV-1 infection, as documented by a rapid HIV test or any FDA-Approved HIV-1 Enzyme or Chemiluminescence Immunoassay (E/CIA) test kit and confirmed by Western Blot at any time prior to study entry. HIV antigen, plasma HIV-1 RNA, or a secondary antibody test by a method other than rapid HIV and E/CIA is acceptable as an alternative test. Alternatively, if a rapid HIV test or any FDA-Approved HIV-1 Enzyme or Chemiluminescence Immunoassay (E/CIA) test is not available, two HIV-1 RNA values ? 2000 copies/mL at least 24 hours apart performed by any laboratory that has CLIA certification, or its equivalent, may be used to document infection.
HIV infection
Known human immunodeficiency virus (HIV) infection or a known HIV-related malignancy. Note: HIV testing is not required unless there is any clinical suspicion that the patient might be HIV positive.
Patients who are HIV+ will be excluded
Patients with known HIV.
HIV infection
HIV infection; there is theoretical concern that the degree of immune suppression associated with the treatment may result in progression of HIV infection
DONOR: Infection with HIV
Known HIV infection
HIV infection (due to increased risk of severe infection and unknown interaction of moxetumomab pasudotox with antiretroviral drugs)
Evidence of HIV infection
HIV negative.
Documentation of HIV status; if participant is HIV positive, HIV-1 infection, as documented by any federally approved, licensed HIV rapid test performed in conjunction with screening (or enzyme-linked immunosorbent assay [ELISA] test kit, and confirmed by Western blot or other approved test, or HIV rapid multispot antibody differentiation assay); alternatively, this documentation may include a record demonstrating that another physician has documented the participant's HIV status based on either: 1) approved diagnostic tests, or 2) the referring physician's written record that HIV infection was documented, with supporting information on the participant's relevant medical history and/or current management of HIV infection\r\n* If the participant is HIV negative, documentation of a negative result for any federally approved, licensed HIV rapid test within 4 weeks prior to study enrollment will suffice; if the initial rapid test is positive, further approved confirmatory test results must be present to document the subject’s HIV status
Has a known history of HIV.
Patients with HIV
Known HIV infection
Known HIV infection.
Patient has a known history of HIV infection (testing not mandatory).
Known HIV infection
Patients with the presence of an infection including abscess or fistulae, or known infection with hepatitis B or C or HIV
Known HIV infection.
Subjects with known HIV infection
HIV infection; patients should provide consent for HIV testing according to the institution’s standard practice
Known HIV infection
Known history of HIV infection.
Known HIV infection.
History of HIV infection.
Known HIV infection
Kown history of HIV.
HIV infection
HIV infection with a last known or suspected CD4 count of <50/mm3
History of HIV disease and/or treatment with anti-HIV agents.
Known HIV infection
Known HIV+ patients.
A positive HIV test result (enzyme-linked immunosorbent assay [ELISA] and Western blot) or history of known HIV; an HIV test will not be required; however, previous medical history will be reviewed
Known active infection with HIV
Known HIV infection.
Known active infection with HIV
Any HIV status
Positive test for human immunodeficiency virus
Human immunodeficiency virus (HIV) test has been obtained within 42 days; participants who test positive for HIV cannot be enrolled on therapeutic part of study, but are still eligible for biology studies
Positive test for human immunodeficiency virus (HIV) at screening;
Known positive test for Human immunodeficiency virus (HIV).
Any positive test for human immunodeficiency virus (HIV) 1/2 antibodies and/or ribonucleic acid (RNA)
Negative human immunodeficiency virus (HIV) test at screening.
Positive human immunodeficiency virus (HIV) test
Positive test for human immunodeficiency virus (HIV)
Positive test for human immunodeficiency virus (HIV)
Positive human immunodeficiency virus (HIV) test at screening
Positive human immunodeficiency virus (HIV) test at screening
Have negative test result for human immunodeficiency virus (HIV) and hepatitis B or C testing
Human immunodeficiency virus (HIV)-positive test result, or history of other immunodeficiency
Positive test for Human Immunodeficiency Virus (HIV)
Known positive test for human immunodeficiency virus (HIV)
Positive test for human immunodeficiency virus (HIV)
Positive test for human immunodeficiency virus (HIV) or history of active tuberculosis
History of positive human immunodeficiency virus (HIV)?1 or HIV?2 serologies or nucleic acid test
History of confirmed positive test for human immunodeficiency virus (HIV)
Human immunodeficiency virus (HIV) positive test result or other immunodeficiency or immunosuppression
Human immunodeficiency virus (HIV) positive test result or other immunodeficiency or immunosuppression
True positive test results for human immunodeficiency virus (HIV) or hepatitis B or C
Primary or secondary immunodeficiency (history of, or currently active), including known history of human immunodeficiency virus (HIV) infection or positive test at screening.
History of known human immunodeficiency virus (HIV) infection or positive HIV test result at screening.
Human immunodeficiency virus (HIV)-positive test result or history of other immunodeficiency
Has a positive test for human immunodeficiency virus (HIV) antibodies.
Positive test for human immunodeficiency virus (HIV)
Any positive test for human immunodeficiency virus (HIV)
Human immunodeficiency virus (HIV)-positive test result or history of other immunodeficiency
Known to be positive for the human immunodeficiency virus (HIV) (a test for HIV at screening is not required)
Positive test for the human immunodeficiency virus (HIV).
Positive human immunodeficiency virus (HIV) test result prior to or at Screening
Positive test for human immunodeficiency virus (HIV) infection
Human immunodeficiency virus (HIV)-positive test result, or history of other immunodeficiency
Human immunodeficiency virus (HIV)-positive test result, or history of other immunodeficiency
Human immunodeficiency virus (HIV) seropositive, with positive confirmatory nucleic acid test
Patients with human immunodeficiency virus (HIV) infection (antibody positive with positive confirmatory molecular test)
Positive test for hepatitis B, C or HIV (Human Immunodeficiency Virus) virus
Positive test for human immunodeficiency virus infection
Positive human immunodeficiency (HIV) test at screening or at any time prior to screening
Human Immunodeficiency Virus (HIV) positive test within 8 weeks of screening
Positive human immunodeficiency virus test result
Positive test for Human Immunodeficiency Virus (HIV)
Positive test result for human immunodeficiency virus (HIV)
Negative human immunodeficiency virus (HIV) screening test
Positive test for Human Immunodeficiency Virus (HIV)
Known to be positive for human immunodeficiency virus (HIV) antibody; NOTE: Does NOT need to be repeated if pre-transplant screening test was negative
Subject has a known history of positive test for Human Immunodeficiency Virus.
True positive test results for human immunodeficiency virus (HIV) or hepatitis B or C
Positive test for human immunodeficiency virus (HIV)
Sero-positive or nucleic acid test (NAT) positive for human immunodeficiency virus (HIV)
Known history of or positive test result for human immunodeficiency virus (HIV)
Positive test result for human immunodeficiency virus.
Human immunodeficiency virus (HIV) test must be negative
Human immunodeficiency virus (HIV) positive test result
Subject has a known history of a positive test for human immunodeficiency virus (HIV) infection.
Subject has a known history of a positive test for human immunodeficiency infection.
Participant who is seropositive or positive in the nucleic acid test for human immunodeficiency virus (HIV)
History of positive human immunodeficiency virus (HIV)-1 or HIV-2 serologies or nucleic acid test
Positive test for human immunodeficiency virus (HIV)
An indeterminate or positive test for antibody to human immunodeficiency virus (HIV-1 or -2).
Positive human immunodeficiency virus (HIV) test
Positive test for Human Immunodeficiency Virus (HIV) 1&2 or known AIDS
History of positive human immunodeficiency virus (HIV)-1 or HIV-2 serologies or nucleic acid test
A positive test for human immunodeficiency virus (HIV) antibody (testing at time of screening is not required).
Positive test for human immunodeficiency virus (HIV) infection
Known positive test for human immunodeficiency virus (HIV)
Positive test for HIV (human immunodeficiency virus)
Subject has a known history of a positive test for human immunodeficiency virus (HIV) infection.
Positive test for human immunodeficiency virus (HIV) (test to be performed within 28 days of first treatment start)
Positive test for Human Immunodeficiency Virus (HIV)
Known history of, or positive test result for human immunodeficiency virus (HIV) infection.
Positive test for Human Immunodeficiency Virus (HIV)
Positive human immunodeficiency virus (HIV) test
Positive test for human immunodeficiency virus (HIV) (testing required prior to registration)
The participant has had a known positive test result for the human immunodeficiency virus.
The participant has had a known positive test result for the human immunodeficiency virus.
Positive test for human immunodeficiency virus (HIV)
Known human immunodeficiency virus infection.
Known human immunodeficiency virus infection
Human Immunodeficiency Virus infection at screening.
Known human immunodeficiency virus infection.
Known human immunodeficiency virus infection
Patients must not be known to be Human Immunodeficiency Virus positive. Testing for Human Immunodeficiency Virus is not mandatory.
Patient has a known history of human immunodeficiency virus infection (testing not mandatory)
Known human immunodeficiency virus infection.
Known human immunodeficiency virus infection.
Known immunosuppressive disease or human immunodeficiency virus infection
Known history of human immunodeficiency virus infection.
Known human immunodeficiency virus infection
Patients with known immunosuppressive disease or known human immunodeficiency virus infection
Known human immunodeficiency virus infection.
Known human immunodeficiency virus infection
Known history of human immunodeficiency virus
Known human immunodeficiency virus infection
Immunosuppressive disease or human immunodeficiency virus infection
Known history of human immunodeficiency virus
Known human immunodeficiency virus infection
Known human immunodeficiency virus infection
Known human immunodeficiency virus infection
Known human immunodeficiency virus infection
Known history of human immunodeficiency virus
Known autoimmune disease, immunosuppressive disease or human immunodeficiency virus infection (i.e., known human immunodeficiency virus [HIV] or hepatitis C)
Known human immunodeficiency virus infection
Known human immunodeficiency virus infection
Patients with known human immunodeficiency virus infection are not to be enrolled in the study
Must not have any known human immunodeficiency virus infection.
Known human immunodeficiency virus infection.
Subject is known to have human immunodeficiency virus infection.
Human immunodeficiency virus infection.
Known human immunodeficiency virus infection.
Known infection with human immunodeficiency virus.
Known human immunodeficiency virus infection.
Known history of Human Immunodeficiency Virus;
Subject is known to have human immunodeficiency virus infection.
Known human immunodeficiency virus infection (pre-study testing not required)
Known human immunodeficiency virus infection
Subject is known to have human immunodeficiency virus infection.
Known human immunodeficiency virus infection
Have a known history of or a positive serologic test for infection with human immunodeficiency virus or human T lymphotrophic virus
Patients with known autoimmune disease, immunosuppressive disease or known human immunodeficiency virus infection
Human immunodeficiency virus infection
Have a known history of human immunodeficiency virus infection.
Subject is known to have human immunodeficiency virus infection
Have known hepatitis B or C, or human immunodeficiency virus infection
Known human immunodeficiency virus infection
History of human immunodeficiency virus infection (testing is not required)
Known human immunodeficiency virus infection.
Known human immunodeficiency virus infection
The participant is known to be positive for infection with the human immunodeficiency virus
Known human immunodeficiency virus infection
Known human immuno virus infection.
History of human immunodeficiency virus infection.
Subject is known to have human immunodeficiency virus infection.
Positive serology for HIV.
Positive serology for human immunodeficiency virus (HIV) or hepatitis C virus (HCV); presence in the serum of the antigen hemoglobin (HBs)
Negative serology for human immunodeficiency virus (HIV)
Negative antiviral serology:
Negative antiviral serology
Evidence of HIV infection or known HIV positive serology.
Negative antiviral serology.
Known positive serology for human immunodeficiency virus (HIV) (baseline testing not required)
Positive HIV serology or viral RNA
PART II: Negative serology for anti-HIV-1/2 and anti-HTLV 1/2
Positive HIV serology (previous records acceptable)
Negative viral serology:
Positive serology for hepatitis B or C, or known human immunodeficiency virus infection (HIV)
Known human immunodeficiency virus (HIV) or a history of active hepatitis B or C as evidenced by laboratory abnormalities in addition to positive serology; testing is not required for patients not suspected of having these conditions
Known human immunodeficiency virus (HIV) positive serology or chronically active hepatitis B or C.
Known positive serology for human immunodeficiency virus (HIV)
Known positive serology for human immunodeficiency virus (HIV).
Positive serology for human immunodeficiency virus (HIV)
Known positive serology for human immunodeficiency virus (HIV), due to potential drug-drug interactions between anti-retroviral medications and the study drugs
Active human immunodeficiency virus (HIV) infection or known HIV positive serology
Patient with known positive serology for human immunodeficiency virus (HIV)
Active human immunodeficiency virus (HIV) infection or known HIV positive serology
Negative serology for human immunodeficiency virus (HIV)
Positive serology for human immunodeficiency virus (HIV)
Active viral hepatitis or active human immunodeficiency virus (HIV) infection. Asymptomatic positive serology is not exclusionary.
PART 1: Evidence of human immunodeficiency virus (HIV) infection or known HIV positive serology
Negative serology for human immunodeficiency virus (HIV)
Known HIV-positive serology.
Evidence of human immunodeficiency virus (HIV) infection or known HIV positive serology
Evidence of human immunodeficiency virus (HIV) infection or known HIV positive serology
History of human immunodeficiency virus (HIV) infection or known positive serology
Evidence of human immunodeficiency virus (HIV) infection or known HIV positive serology
Human immunodeficiency virus (HIV)+ serology
Active human immunodeficiency virus (HIV) infection or known HIV positive serology
Positive results from HIV serology testing, if any available.
Human immunodeficiency virus (HIV) infection based on history of positive serology
Positive serology for human immunodeficiency virus (HIV).
Patient has known positive serology for human immunodeficiency virus (HIV).
Negative human immunodeficiency virus (HIV)-1/2 serology
Patient with known positive serology for human immunodeficiency virus (HIV)
Human immunodeficiency virus (HIV) and hepatitis c negative (serology)
Evidence of human immunodeficiency virus (HIV) infection or known HIV positive serology
Patient with known positive serology for human immunodeficiency virus (HIV)
Current clinically active infectious disease (including positive HIV serology or viral RNA)
Positive serology for HIV.
Negative human immunodeficiency virus (HIV) serology
Patient must not have a history of positive human immunodeficiency virus (HIV) serology
Evidence of human immunodeficiency virus (HIV) infection or known HIV positive serology
Patients with congenital immunodeficiency, chromosomal breakage syndrome, prior organ transplantation, previous malignancy of any type, or known positive human immunodeficiency virus (HIV) serology
Patients with congenital immunodeficiency, chromosomal breakage syndrome, prior organ transplantation, previous malignancy of any type, or known positive HIV serology.
Patients must have negative human immunodeficiency virus (HIV) serology
Positive serology for HIV
Human immunodeficiency virus (HIV) positive serology or AIDS
Negative antiviral serology.
DONOR: History of positive HIV-1 or HIV-2 serology or nucleic acid test
Positive serology test for human immunodeficiency virus (HIV) type 1 and 2, or known history of other immunodeficiency disease
Evidence of HIV infection or HIV positive serology.
Positive serology for Human Immunodeficiency Virus (HIV) or Hepatitis C Virus (HCV); presence in the serum of the antigens HBs
Evidence of human immunodeficiency virus (HIV) infection or known HIV positive serology
Known positive serology for human immunodeficiency virus (HIV) and known history of HIV
DONOR: History of positive HIV-1 or HIV-2 serology or nucleic acid test
Known positive serology for human immunodeficiency virus (HIV) or human anti-mouse antibody (HAMA)
Positive serology for HIV
Infectious disease criteria:\r\n* No active infection; infection controlled with antimicrobial therapy is not excluded\r\n* Human immunodeficiency virus (HIV) negative by enzyme-linked immunosorbent assay (ELISA) or reverse transcription-polymerase chain reaction (RT-PCR) (if ELISA is positive and RT-PCR is negative, the ELISA is considered false positive)\r\n* Hepatitis B and C negative by serology or RT-PCR\r\n* Must complete full screening panel:\r\n** HIV 1, 2 serology and RT-PCR\r\n** Human T-lymphotropic virus (HTLV) 1,2 serology\r\n** Rapid plasma reagin (RPR) serology\r\n** Epstein–Barr virus (EBV) serology\r\n** Cytomegalovirus (CMV) serology\r\n** Herpes simplex virus (HSV) serology\r\n** Varicella zoster virus (VZV) serology
Evidence of HIV infection or known HIV positive serology.
Positive serology for HIV.
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; however, HIV patients treated with regimens that have low cytochrome P450 (CYP450) inhibition may be allowed as long as the patient’s general health and cluster of differentiation (CD)4 counts are within acceptable levels
Patients who are known to be human immunodeficiency virus (HIV)-positive at registration are eligible at the time of registration:\r\n1. Cluster of differentiation (CD)4+ cell count greater or equal to 250 cells/mm^3\r\n2. If patient is on antiretroviral therapy, there must be minimal interactions or overlapping toxicity of the antiretroviral therapy with the experimental cancer treatment; once daily combinations that use pharmacologic boosters may not be used\r\n3. No history of non-malignancy acquired immunodeficiency syndrome (AIDS)-defining conditions other than historical low CD4+ cell counts
Patients with a known history of human immunodeficiency virus (HIV) seropositivity:\r\n* Must have undetectable viral load using standard HIV assays in clinical practice\r\n* Must have cluster of differentiation (CD)4 count >= 400/mcL\r\n* Must not require prophylaxis for any opportunistic infections (i.e., fungal, Mycobacterium avium complex [mAC], or pneumocystis jiroveci pneumonia [PCP] prophylaxis)\r\n* Must not be newly diagnosed within 12 months prior to sub-study registration
Known human immunodeficiency virus (HIV)-positive patients should have a cluster of differentiation (CD)4 count > 250/mm^3
Disease must be cluster of differentiation (CD)30 positive
Patients with known human immunodeficiency virus (HIV) positive must have a cluster of differentiation (CD)4 cell count be >= 350 cells/mm^3 within 14 days prior to study entry (note, however, that HIV testing is not required for entry into this protocol)
Subjects with histopathologic confirmation of intermediate or high-grade primary central nervous system lymphoma (PCNSL) as documented by brain biopsy, or cytology (analysis from cerebral spinal fluid [CSF] or vitrectomy), and cluster of differentiation 20 (CD20) positive; whenever possible, the tumor should be characterized by immunophenotype
A stem cell product collected prior to the infusion of 153Sm-EDTMP must be available, either by peripheral stem cell mobilization or bone marrow harvest prior to trial entry; a minimum of 2 x 10^6 cluster of differentiation (CD)34+ cells/kg ideal body weight is required
Prior treatment with cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapies
A cluster of differentiation (CD)4+ lymphocyte count > 50/mcL will be required within 2 weeks of study participation
On continuous antiretrovirals with cluster of differentiation 4 (CD4) count > 200 cells/ml with sustained undetectable viral load for at least 3 months; (HIV positive women)
Prior treatment with Cluster of differentiation 33 (CD33) antibody Further exclusion criteria apply.
Histologically documented cluster of differentiation (CD) 20-positive B-cell lymphoma classified as relapsed or refractory FL or DLBCL after treatment with at least two prior chemoimmunotherapy regimens that included an anti-CD20 monoclonal antibody (mAb) and for which no other more appropriate treatment option exists
AIDS defined as a CD4 (cluster of differentiation 4) count less then 200 in the context of HIV sero-positivity or chronically is taking immunosuppressive medication such as steroids or transplant related medications.
For non-myeloablative transplants, >= 50% cluster of differentiation (CD)3 donor chimerism at screening
Cluster of differentiation (CD)4 count >= 200 within 120 days prior to enrollment or plasma HIV-1 RNA < 200 copies/mL within 120 days prior to randomization
Use of rituximab and other anti-cluster of differentiation antigen 20 (CD20) antibodies known to have the same epitope as rituximab or anti-cluster of differentiation antigen 20 (CD20) for which the epitope is unknown within 3 months prior to enrollment;
Patients must have at least 3 x 10^6 cluster of differentiation (CD)34+ cells/kg frozen
Have previously received or are ineligible for treatment with blinatumomab; ineligibility will include (but not be limited to) cluster of differentiation 19 (CD19)-negative disease, denial of insurance coverage, physician discretion, and/or patient refusal
Histologically confirmed diagnosis of cluster of differentiation (CD)30-positive ALCL with documented ALK-positive status
Cluster of differentiation (CD)4 count >= 200/uL or >= 15% of peripheral blood lymphocytes
Patients with well controlled human immunodeficiency virus (HIV) infection are eligible if their cluster of differentiation (CD)4 count is > 499/cu mm and viral load is < 50 copies/ml
Patients with known human immunodeficiency virus (HIV) infection are eligible if not on antiviral agents and cluster of differentiation (CD)4 counts are adequate (>= 500)
Availability of >= 2.5 million cluster of differentiation (CD)34+ cells/kg previously apheresed
Patient has a confirmed diagnosis of mantle cell lymphoma with B-lymphocyte antigen cluster of differentiation (CD)20 (CD20) positivity in tissue biopsy
Patients must meet the diagnostic criteria for HPS (at least 5 of the following):\r\n* Fever\r\n* Splenomegaly\r\n* Cytopenia involving >= 2 cell lines\r\n* Hypertriglyceridemia or hypofibrinogenemia\r\n* Tissue demonstration of hemophagocytosis\r\n* Hepatitis\r\n* Low or absent natural killer (NK) cell activity\r\n* Serum ferritin >= 3000 ug/L\r\n* Soluble interleukin (IL)-2 receptor (cluster of differentiation [CD25]) > 2400 U/mL
Human immunodeficiency virus (HIV) positive (+) patients with cluster of differentiation 4 (CD4) counts >= 250 cells/mm^3 on anti-viral therapy
Patients who have known human immunodeficiency virus (HIV) positivity must be on a 3-drug antiviral regimen that does not include zidovudine, and must have a cluster of differentiation (CD)4 count > 100/mm^3 and virus load < 5000 copies/ml, and are placed on a regimen to prevent pneumocystis pneumonia (PCP) reactivation during treatment
INCLUSION CRITERIA FOR ENROLLMENT: Donor cluster of differentiation (CD)3+ chimerism >= 30% measured in peripheral blood or bone marrow
Patients must have primary refractory or first relapse of cluster of differentiation 30 (CD30)+ Hodgkin lymphoma
Known sensitivity to lenalidomide or other thalidomide derivatives or anti cluster of differentiation (CD)20
Cluster of differentiation (CD)4 count >= 200/uL or >= 15% of peripheral blood lymphocytes
Relapsed/refractory MCL: Confirmed diagnosis of mantle cell lymphoma with cluster of differentiation (CD)20 and cyclin D1 through cyclin D3 positivity in tissue biopsy
Must have 4-8 x 10^6 cluster of differentiation (CD)34+ cells/kg (recipient weight) infused on day 0
Availability of autologous peripheral blood stem cell graft, containing at least 6.0 x 10^6 cluster of differentiation 34 positive (CD34+) cells/kg
A minimum of 2 x 10^6 cluster of differentiation 34 positive (CD34+) cells must have been collected
A minimum apheresis collection of 5 million cluster of differentiation (CD)34+ cells/kg of autologous hematopoietic progenitor cells (AHPC)
Patients with acquired immunodeficiency syndrome (AIDS-related illnesses) or known human immunodeficiency virus (HIV) disease must:\r\n* Have a cluster of differentiation (CD)4 count >= 200 cells/uL within 30 days before beginning study therapy\r\n* Be off all antiretroviral therapy (prophylaxis/treatment) more than 60 days before beginning study therapy, and\r\n* Have no evidence of opportunistic infections
Patients must have cluster of differentiation (CD)33 positivity of >= 30%
Cluster of differentiation 4 (CD4) count >= 200/uL
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are eligible; unless the patient’s cluster of differentiation (CD)4+ count is below the institutional lower limit of normal
Patients with a known history of human immunodeficiency virus (HIV) seropositivity: must have undetectable viral load using standard HIV assays in clinical practice; must have cluster of differentiation (CD)4 count >= 400/mcL; must not require prophylaxis for any opportunistic infections (i.e., fungal, mycobacterium avium complex [mAC], or pneumocystis pneumonia [PCP] prophylaxis); must not be newly diagnosed within 12 months prior to re-registration
Adequate autologous stem cell collection, defined as an unmanipulated, cryopreserved, peripheral blood stem cell collection containing at least 2 x 10^6 cluster of differentiation (CD)34+ cells/kg based on patient body weight
Patients with a known history of human immunodeficiency virus (HIV) seropositivity: 1. Must have undetectable viral load using standard HIV assays in clinical practice; 2. Must have cluster of differentiation (CD)4 count >= 400/mcL; 3. Must not require prophylaxis for any opportunistic infections (i.e., fungal, mycobacterium avium complex [mAC], or pneumocystis pneumonia [PCP] prophylaxis); 4. Must not be newly diagnosed within 12 months prior to re-registration
Patients with a known history of human immunodeficiency virus (HIV) seropositivity:\r\n* Must have undetectable viral load using standard HIV assays in clinical practice\r\n* Must have cluster of differentiation (CD)4 count >= 400/mcL\r\n* Must not require prophylaxis for any opportunistic infections (i.e., fungal, mycobacterium avium complex [mAC], or pneumocystis pneumonia [PCP] prophylaxis)\r\n* Must not be newly diagnosed within 12 months prior to re-registration
Patients with any stage of pathologically confirmed cluster of differentiation (CD)3+ acute, lymphoma, chronic, or smoldering subtypes of ATLL
Subjects must be on a prophylactic regimen for Pneumocystis carinii pneumonia, or agree to begin such treatment and remain on treatment until after completion of therapy and until the cluster of differentiation (CD)4 cells are greater than 200/mm^3
Patients with known human immunodeficiency virus (HIV) are not eligible if cluster of differentiation (CD)4 count is =< 200 cell/mm^3 or if receiving antiretroviral therapy
Patients with known human immunodeficiency virus (HIV) who have cluster of differentiation (CD)4+ T cell counts >= 500 cells/mm^3 and who do not require antiretroviral therapy are eligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; if an HIV-positive patient has adequate cluster of differentiation (CD4) counts (CD4 above the lower limit of institutional normal) and is on antiretroviral therapy with newer agents, which are not strong cytochrome (CYP) inhibitors, they will be eligible
Human immunodeficiency virus (HIV)-positive patients on antiviral drugs and/or cluster of differentiation (CD)4 count is inadequate (< 500); if neither condition exists, HIV-positive patients are eligible
Patients with a history of prior treatment with ipilimumab, anti-programmed cell death 1 (PD 1) antibody, cluster of differentiation 137 (CD137) agonist or other immune activating therapy such as anti-cluster of differentiation 40 (CD 40) antibody
Cluster of differentiation (CD)4 count > 400 cells/mm^3
Lymphopenia, cluster of differentiation (CD)4 lymphopenia, leukopenia, and anemia will not render patients ineligible
Histologically documented cluster of differentiation 20 (CD20) positive lymphoma
Patients who are known to be human immunodeficiency virus (HIV) positive must have a normal cluster of differentiation (CD)4 count and undetectable viral load
Participants must have previously untreated cluster of differentiation (CD) 20-positive diffuse large, B-cell lymphoma
For obinutuzumab + Atezo + Pola treatment group: relapsed or refractory FL after treatment with at least one prior chemoimmunotherapy regimen that included an anti-Cluster of Differentiation (CD)20 monoclonal antibody and for which no other more appropriate treatment option exists as determined by the investigator
Cluster of differentiation (CD)4 count >= 200/mcL
Human immunodeficiency virus (HIV)-positive patients with inadequate cluster of differentiation (CD)4 counts or those who are on combination antiretroviral therapy with strong cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) effects are ineligible for this trial
Subjects must have measurable disease defined as at least one tumor lesion of at least 1.5 cm or a peripheral blood cluster of differentiation (CD)5+, CD19+ lymphocyte count of at least 5,000 cells/uL
Patients with a diagnosis of active human immunodeficiency virus (HIV) infection, on anti-retroviral therapy, or with a cluster of differentiation (CD) 4 count less than 200 are ineligible; testing is not required in the absence of clinical findings or suspicion
Patients with a diagnosis of active human immunodeficiency virus (HIV) infection, on anti-retroviral therapy, or with a cluster of differentiation (CD)4 count less than 200 are ineligible due to potential interactions between irinotecan and anti-retroviral medications as well as possible immunosuppressive activity of the study treatment; testing is not required in the absence of clinical findings or suspicion
Patients with human immunodeficiency virus (HIV) are eligible if they are not on antiviral agents and have adequate cluster of differentiation (CD)4 counts (>= 500 mm^3)
Human immunodeficiency virus (HIV)-positive patients with cluster of differentiation 4 (CD4) counts less than the lower limit of institutional normal
Known diagnosis of human immunodeficiency virus (HIV) infection unless patient is fully immunocompetent (cluster of differentiation 4 [CD4] > 200) and patient is not taking antiretroviral therapy
Patients must have an adequate number of cluster of differentiation (CD)34+ stem cells collected to allow for transplantation (defined as >= 2 x 10^6 CD34+ cells/kg body weight); if not previously collected and stored or if previous collection was inadequate, the patients must be willing to undergo stem cell mobilization and collection as per standard practice
Expansion Cohort: patients who have known human immunodeficiency virus (HIV) positivity must be on a 3-drug antiviral regimen that does not include zidovudine and must have a cluster of differentiation (CD4) count > 100/mm^3 and virus load < 5000 copies/mL; they must be placed on a regimen to prevent pneumocystis pneumonia (PCP) reactivation during treatment
Prior treatment with anti-cluster of differentiation (CD)20 monoclonal antibody or alemtuzumab within 2 months prior to start of therapy
Patients with HCL variant (as defined by absence of expression of cluster of differentiation [CD]25 or absence of BRAF V600E mutation)
Prior treatment with anti-cluster of differentiation (CD)20 monoclonal antibody or alemtuzumab within 3 months prior to start of therapy
Documented cluster of differentiation (CD)30+ expression from either original diagnosis or a tumor biopsy in the relapsed setting
Patients with human immunodeficiency virus (HIV) infection are eligible provided their cluster of differentiation 4 (CD4) count is greater than or equal to the institutional lower limit of normal (LLN) (>= 334 cells/uL)
Tumor cell negative for cluster of differentiation (CD)20 (absence of result due to technical problems in the presence of other characteristics suggestive of BL/DLBCL, including genetic and phenotypic features, is not an exclusion criteria)
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy will be eligible unless the cluster of differentiation (CD)4 count is < 200 cells/mm^3 within one month of study enrollment
Previous treatment with SGN-35 or any other prior anti-cluster of differentiation (CD)30-based antibody therapy
Patients with human immunodeficiency virus (HIV) disease will be permitted, only if they are on effective anti-retroviral therapy, have a cluster of differentiation (CD) 4 count greater than 400, and have had no opportunistic infections within the past 6 months
Patients must provide a lymph node sample of at least 1.5 cm in the long axis, or a bone marrow aspiration sample providing at least 5 million cluster of differentiation (CD)20 and/or CD38+ (approximately 10 ml)
History of histologically documented, B-lymphocyte antigen cluster of differentiation 20 plus (CD20+), iNHL
Patients with cluster of differentiation (CD)34 selected auto grafts
Positive for cluster of differentiation (CD)20 via immunophenotyping
Lymphoblasts may have any positive expression of cluster of differentiation (CD)20 for ofatumumab administration
Human immunodeficiency virus (HIV)-infected persons are eligible if they meet other eligibility criteria including the following:\r\n* No prior acquired immune deficiency syndrome (AIDS)-defining condition other than cluster of differentiation (CD)4+ cells nadir < 200/mm^3\r\n* Pre-leukemia CD4+ cell count >= 250/mm^3\r\n* Willing to adhere to antiretroviral therapy regimen with minimal overlapping toxicity and PK interactions with the experimental agents in this study; no zidovudine- and no ritonavir-containing regimens and no 3-drugs-in-1 pill regimens containing pharmacologic boosters are allowed; recommended regimens are integrase inhibitors combined with tenofovir and emtricitabine
Patients with cluster of differentiation (CD)20 positive diffuse large B-cell lymphoma as confirmed by a pathological biopsy report
A cluster of differentiation (CD)4+ lymphocyte count > 50/mcL will be required within 2 weeks of study participation
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are eligible, unless the patient’s cluster of differentiation (CD)4 count is below the institutional lower limit of normal, or the patient is taking prohibited CYP3A4/5 strong inhibitors or inducers
Lymphopenia, cluster of differentiation 4 (CD4) lymphopenia, leukopenia, and anemia will not render patients ineligible
Patients must have relapsed or refractory cluster of differentiation (CD) 20+ lymphoid malignancies with either documented central nervous system (CNS) involvement or peripheral nerve infiltration
If HIV-positive, any cluster of differentiation (CD)4 count will be allowed on study
Prior treatment with cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapies
Human immunodeficiency virus (HIV)-positive patients on antiretroviral medications that are CYP3A4 substrates will be closely monitored; HIV-positive patients will be excluded if they have a cluster of differentiation 4 (CD4) count < 200
Autologous transplant eligible patients must have histologically or cytologically confirmed cluster of differentiation (CD)20 positive relapsed or refractory DLBCL by biopsy within 45 days prior to subject enrollment and must have been previously treated with an anthracycline and rituximab-containing regimen
Adequate autologous graft, defined as an unmanipulated, cryopreserved, peripheral blood stem cell graft containing at least 2 x 10^6 cluster of differentiation (CD)34+ cells/kg based on patient body weight
Immunocompromised patients (other than that related to the use of corticosteroids) including patients known to be human immunodeficiency virus (HIV) positive with low cluster of differentiation (CD)4 count; Note: previous calcineurin inhibitor or previous sirolimus use allowed
If human immunodeficiency virus (HIV) positive, cluster of differentiation 4 (CD4) count must be >= 400
A cluster of differentiation (CD) 4 count > 100/mcL will be required within 2 weeks of study participation
Documented Cluster of Differentiation Antigen 20 (CD20) + B-Cell Chronic Lymphocytic Lymphoma (B-CLL)
Histopathologic confirmation of one of the following cluster of differentiation antigen 20 positive (CD20+) B-cell non-Hodgkin's lymphomas (tissue diagnostic procedures must be performed within 6 months of study entry and with biopsy material available for review):
Availability of previously collected autologous stem cells (at least 3.0 x 10^6 cluster of differentiation [CD]34 cells/kg)
Newly diagnosed cluster of differentiation (CD) 20+ DLBCL with IPI between 3-5
Patient must have cluster of differentiation (CD)34+ stem cells >= 2 x 10^6/kg (actual body weight of the recipient) available for transplantation
Human immunodeficiency virus (HIV)-positive patients who are not receiving: agents with the potential for PK interactions with romidepsin or hepatotoxic antiretrovirals (nucleoside reverse-transcriptase inhibitors [NRTIs]: abacavir, didanosine, emtricitabine, lamivudine, stavudine, and zidovudine), dual protease inhibitor (PI)-based regimens except low-dose boosting with ritonavir, atazanavir, indinavir, maraviroc, and nevirapine may be eligible; additionally, the HIV-positive patients should have a cluster of differentiation (CD)4 count > 250/mm^3; if the specific cause of hepatic dysfunction is unknown, the patient should be worked up for other viral causes of hepatitis and their eligibility determined after consultation with the principal investigator
Immunocompromised patients, this includes human immunodeficiency virus (HIV)-positive patients
Patients known to be human immunodeficiency virus (HIV) positive and currently receiving retroviral therapy are not eligible; note: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for the study
Immunocompromised patients (other than that related to the use of corticosteroids) including patients known to be human immunodeficiency virus (HIV) positive
Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy\r\n* NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
Immunocompromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV) and are receiving antiviral therapy (testing is not part of the protocol)
Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; Note: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
Known to be human immunodeficiency virus (HIV) positive or immunocompromised with posttransplant lymphoproliferative disorder (PTLD)
Immunocompromised patients
Immunocompromised patients with increased risk of opportunistic infections, including known HIV-positive patients
Immunocompromised patients (other than that related to the primary oncologic diagnosis or to the use of corticosteroids) including patients known to be human immunodeficiency virus (HIV) positive are not eligible
Immunocompromised status because of current known active infection with HIV or because of the use of immunosuppressive therapies for other conditions
Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive
Human immunodeficiency virus (HIV) positive or immunocompromised
Immunocompromised patients are excluded
Immunocompromised subjects, e.g., subjects who are known to be serologically positive for human immunodeficiency virus (HIV).
Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy
Immunocompromised patients, e.g. patients known to be serologically positive for HIV. Patients do NOT need to be tested for HIV in order to enroll on study
Immunocompromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV)
Immunocompromised patients
Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive
Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy
Immunocompromised patients
Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial; patients with HIV on antiretroviral therapy other than zidovudine (AZT) and/or stavudine and without prior acquired immunodeficiency syndrome (AIDS) defining conditions and adequate CD4 count (> 400) are eligible
Immunocompromised patients or patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy
Immunocompromised
Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
Immunocompromised patients (other than that related to the use of corticosteroids) including patients known to be human immunodeficiency virus (HIV) positive
Immunocompromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV).
Immunocompromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV)
Patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy
Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy
Immunocompromised patients, including patients known to be HIV positive
Immunocompromised patients (other than that related to the use of corticosteroids) including patients known to be human immunodeficiency virus (HIV) positive
Immunocompromised patients (other than that related to the use of corticosteroids) including patients receiving highly active antiretroviral therapy (HAART) treatment
Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy
Immunocompromised patients e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV)
Immunocompromised patients (other than that related to the use of corticosteroids) including patients known to be human immunodeficiency virus (HIV) positive with cluster of differentiation (CD)4 counts < 200
Is immunocompromised (i.e. congenital immunodeficiencies), including subjects known history of infection with human immunodeficiency virus
Immunocompromised subjects;
Is immunocompromised, including subjects with known human immunodeficiency virus (HIV) infection
Immunocompromised patients, including patients with known HIV infection;
Immunocompromised participants, including participants known to be infected with human immunodeficiency virus (HIV).
Immunocompromised patients
Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy\r\n* NOTE: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive
Immunocompromised patients (other than that related to the use of corticosteroids) including patients confirmed to be human immunodeficiency virus (HIV) positive or have active viral hepatitis
Immunocompromised patients, including those with human immunodeficiency virus (HIV)
Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: patients with a known history of HIV infection are not eligible for this trial
Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
Immunocompromised subjects or those with autoimmune conditions, active hepatitis or positive for human immunodeficiency virus (HIV)
Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
Immunocompromised patients (other than that related to the use of corticosteroids) including patients known to be human immunodeficiency virus (HIV) positive
Immunocompromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV).
Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive
Immunocompromised patients (other than that related to the use of corticosteroids) including patients known to be human immunodeficiency virus (HIV) positive
Immunocompromised patients (other than that related to the use of corticosteroids) with the exception of patients known to be human immunodeficiency virus (HIV) positive and have a cluster of differentiation 4 (CD4) count > 400 and do not require antiretroviral therapy
Immunocompromised patients (other than that related to the use of corticosteroids) including patients known to be human immunodeficiency virus (HIV) positive, per medical doctor (MD) discretion
Immunocompromised subjects, e.g., subjects who are known to be serologically positive for human immunodeficiency virus;
Subject is immunocompromised
Immunocompromised subjects, including subjects known to be infected with human immunodeficiency virus (HIV).
Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
Immunocompromised patients
Immunocompromised patients or patients known to be human immunodeficiency virus (HIV) positive and currently receiving combination antiretroviral therapy; patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
Immunocompromised status
Immunocompromised patients (other than that related to the use of corticosteroids) including patients known to be HIV positive with a CD4 count of < 400
Immunocompromised participants with primary or secondary immunodeficiency
Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy (HIV testing not required); NOTE: patients known to be HIV positive, but without clinical evidence of an immunocompromised state (cluster of differentiation [CD]4 > 200, viral load undetectable, on antiretroviral therapy), are eligible for this trial
Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
Immunocompromised (positive human immunodeficiency virus [HIV] test, transplant recipient, received chemotherapy for cancer, or taking immunosuppressant drugs)
Immunocompromised subjects, including patients with human immunodeficiency virus
Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive (HIV 1/2 antibodies) and currently receiving antiretroviral therapy
Has a known history of human immunodeficiency virus (HIV) infection. HIV testing is not required unless mandated by the local health authority.
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies). No HIV testing is required unless mandated by local health authority.
Has a known history of human immunodeficiency virus (HIV) infection. HIV testing is not required unless mandated by the local health authority.
Known history of human immunodeficiency virus (HIV) infection. HIV testing is not required unless mandated by local health authority.
Known history of human immunodeficiency virus (HIV) infection. HIV testing is not required unless mandated by local health authority.
Known history of human immunodeficiency virus (HIV) infection. HIV testing is not required unless mandated by local health authority.
Patients known to be positive for human immunodeficiency virus (HIV) are not eligible
Patient who are known to be serologically positive for human immunodeficiency virus (HIV)
Known human immunodeficiency virus (HIV)-positive
Known human immunodeficiency virus (HIV) positive
Known human immunodeficiency virus (HIV) positive status
The subject is known to be positive for the human immunodeficiency virus (HIV)
Known human immunodeficiency virus (HIV) positive status
Participants with known human immunodeficiency virus (HIV)-positive status are ineligible
Known to be human immunodeficiency virus (HIV) positive.
Known human immunodeficiency virus (HIV)-positive participants are ineligible
Known human immunodeficiency virus (HIV)-positive
Known human immunodeficiency virus (HIV)-positive participants are ineligible
Participant known to be human immunodeficiency virus (HIV)-positive
Known human immunodeficiency virus (HIV) positive
Known to be human immunodeficiency virus (HIV) positive
Known positive for human immunodeficiency virus (HIV)
Patient is known to be human immunodeficiency virus (HIV)-positive
Patients known to be human immunodeficiency virus (HIV)-positive
Known human immunodeficiency virus (HIV) positive
Patient known to be human immunodeficiency virus (HIV)-positive and requiring antiretroviral therapy
Known human immunodeficiency virus (HIV) positive (testing not required)
Known to be human immunodeficiency virus (HIV)-positive
Known human immunodeficiency virus positive (HIV+) patients
Positive for known human immunodeficiency virus (HIV) Infection
Subject is known to be positive for human immunodeficiency virus (HIV); HIV testing is not required
Known to be human immunodeficiency virus positive (HIV+)
Known human immunodeficiency virus (HIV)-positive status
Patients who are known to be serologically positive for human immunodeficiency virus (HIV)
Known human immunodeficiency virus (HIV)-positive
Known human immunodeficiency virus (HIV) positive patients
Known human immunodeficiency virus (HIV) positive
Known human immunodeficiency virus (HIV) positive
Known human immunodeficiency virus (HIV)-positive status
Known human immunodeficiency virus (HIV)-positive status
Known human immunodeficiency virus (HIV)-positive
Known to be positive for the human immunodeficiency virus (HIV); note: HIV-testing is not required for eligibility, but if performed previously and was positive, the subject is ineligible
Have known (previously documented) positive results for human immunodeficiency virus (HIV).
Known human immunodeficiency virus (HIV) positive
Known to be human immunodeficiency virus (HIV)-positive
Patients known to be human immunodeficiency virus (HIV)-positive
Patients who are known to be (i.e. documented in medical records) human immunodeficiency virus (HIV) positive are not eligible
Known human immunodeficiency virus (HIV) positive
The subject is known to be positive for the human immunodeficiency virus (HIV); Note: baseline HIV screening is not required
Known to be human immunodeficiency virus positive
Patients known to be human immunodeficiency virus (HIV)-positive
Known to be human immunodeficiency virus positive (HIV+)
Known human immunodeficiency virus (HIV)-positive status
Known to be human immunodeficiency virus positive
Known human immunodeficiency virus (HIV)-positive status
Known human immunodeficiency virus (HIV) positive (testing not required).
known human immunodeficiency virus infection (positive HIV antibodies).
Patients known to be positive for human immunodeficiency virus (HIV)
Known human immunodeficiency virus (HIV)-positive status
Patients known to be human immunodeficiency virus (HIV) positive
Known human immunodeficiency virus (HIV) positive
Known human immunodeficiency virus (HIV)-positive patients
Patient is known to be human immunodeficiency virus (HIV)-positive
Known human immunodeficiency virus (HIV)-positive patients are excluded from the study
Known human immunodeficiency virus (HIV) positive
Known human immunodeficiency virus (HIV) positive
Patient is known to be human immunodeficiency virus (HIV)-positive.
Known to be human immunodeficiency virus positive
Patients who are known to be serologically positive for human immunodeficiency virus (HIV).
Known human immunodeficiency virus (HIV)-positive individuals
Subjects with known positive human immunodeficiency virus (HIV) status
Have known (previously documented) positive results for human immunodeficiency virus (HIV).
Known human immunodeficiency virus (HIV)-positive individuals
Known human immunodeficiency virus (HIV)-positive patients are excluded from the study
Known positive for human immunodeficiency virus (HIV); baseline HIV screening is not required
Known human immunodeficiency virus (HIV) positive
Known human immunodeficiency virus (HIV) positive
Patients must not be known to be human immunodeficiency virus (HIV)-positive
Known to be human immunodeficiency virus positive
Patients who are known to be human immunodeficiency virus (HIV) positive
Patients who are known to be human immunodeficiency virus (HIV) positive are not eligible
Known to be human immunodeficiency virus (HIV) positive (testing not mandatory)
Patients who are known human immunodeficiency virus (HIV) positive are not eligible
Known to be positive for human immunodeficiency virus (HIV)
Known positive for human immunodeficiency virus (HIV)
Known positive status for human immunodeficiency virus (HIV)
Known to be human immunodeficiency virus positive
Known positive status for human immunodeficiency virus (HIV)
Known human immunodeficiency virus (HIV)-positive individuals
Known human immunodeficiency virus (HIV) positive
Individuals who are known to be human immunodeficiency virus (HIV)-positive are excluded from this study
Patients known to be human immunodeficiency virus (HIV) positive
Known to be human immunodeficiency virus (HIV) positive
Known positive status for human immunodeficiency virus (HIV)
Patients known to be human immunodeficiency virus (HIV)-positive
Known or suspected human immunodeficiency virus (HIV) or serologically positive
Subjects known to be human immunodeficiency virus (HIV) positive
Patients must not be known to be human immunodeficiency virus (HIV) positive
Known human immunodeficiency virus (HIV) positive patient
Patients known to be positive for human immunodeficiency virus (HIV) are not eligible
Known positive status for human immunodeficiency virus (HIV)
Known human immunodeficiency virus (HIV) positive
Known to be human immunodeficiency virus (HIV) positive
Known human immunodeficiency virus (HIV) positive
Known to be human immunodeficiency virus positive (HIV+)
Subjects with known positive human immunodeficiency virus (HIV) status.
Patients known to be human immunodeficiency virus (HIV) positive
The subject is known to be positive for the human immunodeficiency virus (HIV); Note: baseline HIV screening is not required
Known human immunodeficiency virus (HIV)-positive patients
Known or suspected human immunodeficiency virus (HIV) or serologically positive
Participants known to be positive for Human Immunodeficiency Virus (HIV).
Patients known to be human immunodeficiency virus (HIV) positive or known to have hepatitis B and/or C are excluded
Known to be human immunodeficiency virus (HIV) positive
Patients known to be human immunodeficiency virus (HIV)-positive are ineligible
Known to be human immunodeficiency virus (HIV) positive
Patients with known positive human immunodeficiency virus (HIV) are excluded
Known positive status for human immunodeficiency virus (HIV)
Known positive status for human immunodeficiency virus (HIV)
Known human immunodeficiency virus (HIV)-positive patients and those with known hepatitis B or C are excluded from the study
Is known to be Human Immunodeficiency Virus (HIV) positive
Known human immunodeficiency virus (HIV) positive
Patients known to be human immunodeficiency virus (HIV) positive
Known history of human immunodeficiency virus (HIV) positive.
Known positive status of human immunodeficiency virus (HIV)
Known to be positive for human immunodeficiency virus (HIV).
Subjects known to be positive for Human immunodeficiency virus (HIV) infection.
Known human immunodeficiency virus (HIV) positive
Known human immunodeficiency virus (HIV)-positive patients are ineligible
Known human immunodeficiency virus (HIV) positive.
Known human immunodeficiency virus (HIV) positive status.
Patients known to be human immunodeficiency virus (HIV) positive are not eligible for the study
Ongoing or active infection, or known human immunodeficiency virus (HIV) positive
Known human immunodeficiency virus (HIV) positive
Known human immunodeficiency virus (HIV) positive status
Known positive status for human immunodeficiency virus (HIV)
Patients who are known to be human immunodeficiency virus (HIV) positive are not eligible for this study
Known human immunodeficiency virus (HIV)-positive individuals or with any immunodeficiency status
Patients may not be known to be human immunodeficiency virus (HIV)-positive; HIV testing is not required for study participation
Known history of human immunodeficiency virus (HIV) positive
Known human immunodeficiency virus (HIV) positive
Patients known to be human immunodeficiency virus (HIV)-positive
Patients known to be human immunodeficiency virus (HIV)-positive
Known positive for human immunodeficiency virus (HIV)
Known human immunodeficiency virus (HIV) positive
Patient has known, uncontrolled human immunodeficiency virus (HIV)-positive diagnosis
Individuals known to be human immunodeficiency virus (HIV)-positive may not participate in this study
Known human immunodeficiency virus (HIV) positive patients
Patients known to be human immunodeficiency virus (HIV) positive
Patients known to be human immunodeficiency virus (HIV) positive
Known human immunodeficiency virus (HIV) positive or HIV-related malignancy.
Known human immunodeficiency virus (HIV) positive (testing not required).
